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5-HT2B RECEPTOR-MEDIATED CARDIAC VALVULOPATHY
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Virginia Commonwealth University, 2018

Major Director: Małgorzata Dukat, Ph. D.
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Co-director: Dr. Richard A. Glennon, Ph. D.
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5-HT2B receptor agonism causes cardiac valvulopathy, a condition characterized by
thickening of the heart valves and as a result, regurgitation of blood within the heart. The
anti-obesity drug fenfluramine, which was originally prescribed as an anorectic, was
withdrawn from the market due to causing cardiac valvulopathy. Fenfluramine, after

xx

metabolism by N-dealkylation, produces the metabolite norfenfluramine, which acts as a
more potent valvulopathogen. The same was seen with MDMA (ecstasy), a popular drug
of abuse, which is metabolized by N-dealkylation to produce MDA, a more potent
valvulopathogen. Glennon and co-workers. studied a series of 2,5-dimethoxy-4substituted phenylisopropylamines (DOX type) hallucinogens and determined their
affinities at the three types of 5-HT2 receptors. A high correlation was found between the
affinities of these molecules at 5-HT2A and 5-HT2B receptors. Therefore, these
hallucinogens have a high possibility of causing valvulopathy, which gives rise to a new
class of valvulopathogens.

Since certain hallucinogens have the common phenylisopropylamine structural scaffold
as that of MDA and norfenfluramine, we conducted 3D-QSAR studies to identify the
common structural features of these molecules that are responsible for their high
affinities. We were unable to obtain a suitable CoMFA and CoMSIA model for 5-HT2B
receptors, but we were able to obtain an internally and externally validated model for 5HT2A receptor affinities which indicated the hydrophobicity of the substituent at the 4position was essential for high affinity. Following up with this evidence, we conducted a
correlation analysis for the hydrophobicity (π-value) of the 4-position substituent and
found a positive correlation between the π-value and the affinity of the molecules. The
same results were not observed for the volume of the substituents.

We docked the molecules into the 5-HT2B receptor and successfully generated models of
the putative interactions made by the DOX molecules and the receptor. In order to
compare their binding modes with respect to known valvulopathogens, we also generated

xxi

models for norfenfluramine and MDA. Our docking results revealed that DOX molecules
bind in a more or less similar manner to valvulopathogens MDA and norfenfluramine.
Ours is the first in silico model developed for the potent valvulopathogen MDA and the
hallucinogenic DOX series of molecules.

xxii

I. Introduction
Cardiac valvulopathy is a condition wherein prolonged exposure of certain drugs
(valvulopathogens) causes thickening of the bicuspid and tricuspid valves. 1 It is
histologically characteristic and leads to regurgitation of blood within the ventricles,
resulting in cardiac failure.1 There are two classes of valvulopathogens - ergolines and
phenylisopropylamines.2 The anti-obesity drug fenfluramine was recalled in 1997 for
causing valvulopathy.3 Due to the structural similarity of fenfluramine with MDMA
(ecstasy), Glennon and co-workers proposed that it has a potential to cause
valvulopathy.4 Follow up studies confirmed valvular damage seen in regular users of this
empathogen.4 Just like fenfluramine gets metabolized by N-dealkylation to produce a
more potent valvulopathogen, MDMA also produces the potent N-demethlyated
metabolite, MDA.5
Valvulopathy is caused due to agonism of 5-HT2B receptors.6 However, no
evidence has yet confirmed if all agonists of 5-HT2B receptors cause this condition. For
instance, LSD is a 5-HT2B agonist, yet there has been no evidence of it causing
valvulopathy.7 Therefore, it is unclear if it is due to a biased agonism of the 5-HT2B
receptor, or the receptor localization that may increase the likelihood of causing this
condition. A majority of the ergolines involved in cardiac valvulopathy are prescribed to
treat Parkinsonism (cabergoline, pergolide, bromocriptine and dihydroergocriptine).7 The
remainder are used to treat migraine (methysergide, ergotamine).5 Low doses of
1

cabergoline are used to treat hyperprolactinemia (excess of prolactin secretion by the
pituitary gland).7 The lower dose of cabergoline in hyperprolactinemic patients puts them
at a lower risk than Parkinson's patients.7 In the case of cabergoline users of < 3 mg daily,
they were five times more likely to develop valvulopathy, whereas those on > 3 mg daily
were fifty times more likely.7 Therefore, a high dose for prolonged periods of time vastly
increases the likelihood of developing cardiac valve disease.7 The SAR of these ergolines
at 5-HT2B receptors has been vaguely determined in that 8α-aminoergolines act as
antagonists.2
Phenylisopropylamines are a class of hallucinogens and CNS-acting agents that
are abused recreationally and used to treat CNS-related disorders.8 Thus far, there have
been no structure-affinity relationship studies conducted on phenylisopropylamines
exclusively to determine the features that make norfenfluramine and MDA such potent
valvulopathogens.
A series of hallucinogenic 2,5-dimethoxy-4-substituted phenylisopropylamine
compounds (DOX) were studied by Glennon et al. to distinguish their selectivity at 5-HT2A,
5-HT2B and 5-HT2C receptors.9 The findings of this study showed a strong correlation
between the affinity of these compounds at 5-HT2A and 5-HT2B receptors, indicating them
to be directly proportional to each other.9 It is therefore likely that this class of agents that
bind with high affinity at 5-HT2A receptors may bind with a proportionally high affinity to 5HT2B receptors as well, implicating them in cardiac valvulopathy. The functional activity of
a majority of these compounds is unknown at 5-HT2B receptors, but the 4-bromo and 4iodo substituted compounds (DOB and DOI, respectively) are agonists.10 Our goal is to
determine the structure-activity relationships of these compounds by conducting 3D2

QSAR and docking studies, following up with HINT analysis to validate our docking
studies.
The X-ray crystal structure of the 5-HT2B receptor was determined with ergotamine
and LSD, both structurally constrained analogs of the phenylisopropylamine scaffold. 11,12
In contrast, the isopropylamine system is freely rotatable in norfenfluramine, MDA and
DOX molecules, which necessitated conformational studies. We used the template of the
crystal structures of 4-ethyl and 4-methoxy substituted DOX molecules (DOEt and TMA)
to sketch the remainder of the molecules.13 The crystal structures for norfenfluramine and
MDMA were available and were used to sketch them in Sybyl X2.1.1.14,15
The receptor-ligand interactions seen for LSD and ergotamine show the
involvement of the transmembrane helices 3, 5, 6, and 7.11,12 Findings from the study also
determined the same interactions with norfenfluramine.11 We have validated the quality
of our models with respect to this prior model. There are no prior models for DOX
molecules or MDA with the 5-HT2B receptor, but multiple models have been generated
with 5-HT2A receptors for DOB and DOI, which are extensively studied for their high
affinity at 5-HT2A receptors.16-18 Our docking studies will be compared against those of
the prior models for reference. Nevertheless, the models were based on homology
modeling and were published prior to the 5-HT2B crystal structure, our model might be a
more accurate and the latest representation of the ligand-receptor interactions.
In our studies, we will explore the similarities of valvulopathogens and DOX
molecules, both with 3D-QSAR studies and docking. Our modeling will help provide
insights of the potential ligand-receptor interactions for a new class of valvulopathogens.
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II. Background
1. Valvulopathy
In September of 1997, the FDA and the pharmaceutical company Wyeth-Ayerst withdrew
the popular anti-obesity drugs fenfluramine (Pondimin®) and dexfenfluramine (Redux®)

Figure 1. Diagram of the heart and the various types of atrial and ventricular
valves affected in drug induced cardiac valvulopathy or valvular heart disease
(VHD).1
(Left ventricle = LV; LA = Left atrium; RV = Right ventricle; RA = Right atrium;
PM = Papillary muscles; IS = Interventricular septum)
4

from the market.3 This Class 1 recall by the FDA was due to increased findings of
abnormal echocardiograms in patients taking fenfluramine and the combination therapy
of fenfluramine and phentermine (aka fen-phen) in a seminal paper published by Connolly
et al.19 Phentermine, however, showed no evidence of causing such anomalies. The
findings were not unprecedented because a similar phenomenon was observed in ergot
alkaloid (pergolide, cabergoline, dihydroergotamine) users.1 Some patients undertaking
anti-obesity treatment with fenfluramine and norfenfluramine underwent valve
replacement

surgery

due

to

developing

valvular

disease.6,20

The

abnormal

echocardiograms showed thickening of the cardiac valves (aortic, tricuspid and mitral)
(Figure 1) and subsequent regurgitation of blood back to the ventricles. The heart valves
are composed of three layers – the fibrosa – facing the outflow surface and composed of
dense collagen, the spongiosa – composed of loose collagen and proteoglycans, and the
ventricularis – facing the inflow surface composed of collagen and the inflow surface.1
The extracellular matrix (ECM) of valvular tissue is responsible for the regular
maintenance and repair of the valves. It is predominantly composed of proteoglycans,
collagen, and elastin.1 Changes in this ECM are responsible for producing heart diseases,
including valvulopathy. The terms ‘drug-induced valvulopathy’ and ‘valvular heart
disease’ (VHD) were thus used to identify this phenomenon.1 VHD results in cardiac
insufficiency and eventually death, due to the regurgitation of blood and the inability of
the ventricles to maintain cardiac output.1,20 The cause for this occurrence was unknown
until its target was identified to be the 5-HT2B receptor.6 Further studies revealed that
agonism of cardiac 5-HT2B receptors caused valvular thickening.6 The frequency of
occurrence was varied in different case studies, i.e., 6%-30%. A meta-analysis of these
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studies reported that one in eight patients receiving fenfluramine for more than ninety
days developed valvulopathy.20 Hence, the incidence of valvulopathy was governed by
several factors such as dosage, length of exposure, signaling pathways associated with
5-HT2B receptor agonism, and drug class.1 This effect was not solely attributed to
fenfluramine and related analogs. Other classes of agents such as ergolines, were also
implicated.7

Since

thickening

of

heart

valves

was

attributed

to

increased

activation/agonism of the 5-HT2B receptors in the heart, the endogenous ligand 5-HT was
also on the gamut of suspects that caused valvulopathy.1 An SD (Sprague Dawley) rat
model of subcutaneous injection of 5-HT for seven days showed thickening of the valves
characterized by increased glycosaminoglycans and a lower proportion of collagen.21
Anorexigen-exposed valves have distinct histological features in comparison to other
valvular disorders, such as floppy rheumatic valves or carcinoid heart disease, whereas
carcinoid syndrome shows thickening of the valves, accompanied by increased
vasculature and leukocytes.6 Carcinoid syndrome is caused by elevated levels of
serotonin produced by neuroendocrine tumors.22 McDonald et al.21 demonstrated that
drug-induced valvulopathy is characterized by increased amounts of glycosaminoglycans
(GAGs) in valvular tissue. The recall of norfenfluramine was followed by that of ergolines
(e.g. pergolide, used to treat Parkinsonism).23 Studies on 5-HT2B receptor agonism are
lacking in a specific preclinical animal model for the detection of valvulopathy.1 However,
they were demonstrated in SD rats and cynomolgus monkeys to show higher levels of 5HT2B receptor and serotonin transporter (SERT).1 The valvulopathy due to agonism at 5HT2B receptors is caused by a specific downstream signaling pathway.1 The 5-HT2B
receptor has multiple downstream effectors in producing its effects and while some are

6

unique to it, others are characteristic to the 5-HT2 subfamily of receptors, such as G q
coupled signaling.6

2. Serotonin receptors

5-HT receptors are a group of centrally and peripherally distributed receptors
involved in neurotransmission.24,25 They are both excitatory and inhibitory in nature by
their endogenous ligand 5-hydroxytryptamine (5-HT), aka serotonin.24 5-HT receptors are
involved in the regulation of several other neurotransmitters such as dopamine,
norepinephrine, gamma amino butyric acid (GABA), glutamate, and acetylcholine.25 Due
to their ubiquitous nature in the central nervous system, they are vital for several
developmental processes such as memory, learning, and behavior in several vertebrate
and invertebrate beings.26 In humans, they are highly expressed in the medial prefrontal
cortex (mPFC), which is responsible for executive function, decision making, and
cognitive skills.26,27 These receptors are the oldest neurotransmitters/hormones in
evolution (700 – 800 million years) and have been expressed in a number of different
organisms, including single cell eukaryotes such as paramecia, planaria, Caenorhabditis
elegans (nematodes), drosophila, and man. 27 More recently, a novel serotonin receptor
was found in the larvae of Pieris rapae, a small white butterfly.28 The cDNA, named Pr5HT8, has a relatively low similarity to any of the known serotonin receptor classes.28 They
were expressed and tested in HEK293 cells to show activation (due to an increase in
intracellular calcium levels) with low (<10 nM) concentrations of 5-HT and did not affect
intracellular cAMP levels even at high (>10 μM) concentrations of 5-HT.28 These were
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reported via a BLAST sequence search to be found exclusively in the insect genome, but
not in the mammalian.28
Represented below (Figure 2) is a classification of 5-HT receptors. 5-HT receptors are
primarily G-protein coupled receptors (GPCRs), except for 5-HT3 receptors, which belong
to the super family of Ligand Gated Ion Channel Receptors (LGICRs) (Figure 2 and 3).25

5-HT receptors

5-HT1

5-HT2

5-HT3

5-HT4

5-HT5

5-HT1A

5-HT2A

5-HT3A

5-HT5A

5-HT1B

5-HT2B

5-HT3B

5-HT5B

5-HT1D

5-HT2C

5-HT3C

5-HT6

5-HT7

5-HT1E
5-HT1F

Figure 2. Representation of the 5-HT class and their subclasses of receptors.

Bennett and Snyder in 1976 were the first investigators that employed radioligand binding
techniques in pursuit of discovering 5-HT receptors using rat cortical membrane
preparations.29 In 1979, Peroutka and Snyder helped distinguish 5-HT1 and 5-HT2
receptors using three radioligands, 3[H]5-HT, 3[H]spiperone, and 3[H]LSD.30 The initial
8

classification of 5-HT receptors was based on the ability of the receptors to be blocked by
morphine (labeled as M), or dibenzyline (labeled as D).27 Subsequently, the newer
receptors were discovered between 1987 and 1992.27 5-HT3 receptors were discovered
when it was found they were unable to be blocked by either morphine or dibenzyline.27

ION CHANNEL (s)
5-HT3A
5-HT3B
5-HT3C

-VE
5-HT1A

5-HT1B

G-PROTEIN COUPLED RECEPTORS

Gs

Gi/o

+VE
5-HT4

5-HT6

cAMP

5-HT1D

5-HT7

5-HT1E

5-HT5A

5-HT1F

5-HT5B
5-HT2A

PLC

Gq

5-HT2B
5-HT2C

Figure 3. 5-HT receptors and representation of their signal transduction. (-VE =
negative; +VE = positive). (cAMP = cyclic adenosine monophosphate; PLC =
phospholipace C).
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Streamlining the classification of 5-HT receptors began in 1993 when the Serotonin Club
Receptor Nomenclature Committee laid down guidelines based on operational, structural,
and transductional information (Figure 3).27 The aforementioned three prerequisites, were
equally weighted to facilitate proper classification.27 The 5-HT1E receptor is highly
conserved and plays an important physiological role in mammalian brain.27 Since its role
was determined, it is no longer nominated in lower case, which indicates the physiological
role has yet to be determined (example, 5- ht1E in lieu of 5-HT1E). Other subclasses (5HT1F, 5-HT5A, 5-HT5B, and 5-HT6) have also recently received the uppercase
nomenclature after their physiological functions were delineated.27 5-HT1F receptors have
been targeted to treat migraine27 with indole derivatives and the proposed 5-HT1B/1D
agonist naratriptan.27 5-HT2 receptors are single protein molecules with a high degree of
homology and are 458-471 amino acids in length. 5-HT2 receptors are distributed
centrally and peripherally. 5-HT2A receptors are located in vascular smooth muscle,
platelets, lung, the CNS and the GI tract. Initially 5-HT2B receptors were found to be
located peripherally, and 5-HT2C receptors were located centrally.25 The 5-HT2 receptor
was renamed 5-HT2A, and the 5-HT1C receptors were renamed 5-HT2C.25 Recent
advancements on the structural information of 5-HT receptors including i.e., X-ray crystal
structures of 5-HT2B and 5-HT3 receptors, enabled efforts in studying the mechanism of
action/binding modes of known ligands at 5-HT2 [PDB ID: 4IB4, 5TVN] and 5-HT3 [PDB
ID: 4PIR] receptors, respectively.11,12,31
"Higher end" 5-HT receptors such as 5-HT5, 5-HT6, and 5-HT7, were more recently
discovered, and their functions elucidated.32 Thus, there was an initial lack of selective
agents for the various types of 5-HT receptors.33 This vacuum made characterizing the
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variety of receptors a challenging task. However, through the years, selective agents have
been developed for several serotonergic receptors. Additionally, the serotonin hypothesis
of depression and related illnesses makes the serotonin receptor family a primary target
for antidepressants on the market.33
The three types of 5-HT2 receptors, 5-HT2A, 5-HT2B, and 5-HT2C receptors, have been
extensively studied and have 46-50% homology.34 They are grouped based on close
sequence homology, the presence of similar exon and intron patterns, and the same
transduction systems. They are coupled to G q/11 and increase the hydrolysis of PIP2 to
form inositol phosphate and diacyl glycerol (DAG) which results in an increase of
intracellular calcium levels. Early on (i.e., late 1950s), 5-HT2 receptors were the first to be
discovered and were blocked by dibenzyline (D-type) as discovered by Gaddum and
Picarelli,27 but much later renamed as 5-HT2 receptors by Peroutka and Snyder.30
Gaddum and Picarelli also identified a second group of receptors (M-type) now
recognized as 5-HT3 receptors.27 The three receptors were named based on agreement
at the Serotonin Club Receptor Nomenclature Committee meeting in Houston.
a) 5-HT2A receptors
5-HT2A receptors are the quintessential 5-HT2 receptors and have been studied for the
longest time for their involvement in disease states such as mood related disorders. 24
Activation of 5-HT2A receptors results in the activation of PLCβ and inositol phosphates,
followed by Ca2+ release.34 Depending on the nature of the tissue, different activation
signals lead to different downstream effectors. For example, activation of 5-HT2A
receptors may also occur in conjunction with intracellular calcium release and Ca 2+ influx
from voltage-dependent calcium channels in vascular or tracheal smooth muscles. 34
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CNS-penetrating agonists of 5-HT2A receptors were reported to possess hallucinogenic
activity, and were widely studied, such as 1-(2,5-dimethoxy-4-iodophenyl)propan-2amine (DOI), dimethyltryptamine (DMT), psilocybin, and mescaline to name a few, to
develop radioligands and serve in conducting biological activity tests in 5-HT2 type
receptors.8 Psilocybin (found in the Psilocybe genera of mushrooms), mescaline (peyote
cactus), and DMT (in ingredients of ayahuasca brew) are naturally occurring
hallucinogens. The abovementioned ligands , although do not bind exclusively to 5-HT2A
receptors, their selectivity can be harnessed to serve as radioligands for the other 5-HT2
type receptors (5-HT2B and 5-HT2C).25 5-HT2A receptors have served as an indispensable
target for the study and development of antipsychotics. In the realm of antipsychotics, 5HT2A antagonists were amongst the more popular classes – for example, ketanserin,
risperidone, trazodone, and clozapine, to name a few.25 It was also noted that the HTR2A
gene I197V allele polymorphism on chromosome 13 is responsible for the different
responses upon treatment with clozapine.35,36
5-HT2A receptors in recent years were found to dimerize with the metabotropic
glutamate (mGlu2) receptor and facilitate increasing dopaminergic levels in the brain,
which plays an important role in attention and learning.27 Among their other functions, 5HT2A receptors are also responsible for mediating smooth muscle growth and potentiating
growth factors.27
b) 5-HT2B receptors
i. Distribution of 5-HT2B receptors
5-HT2B receptors belong to the G-protein coupled class of receptors and are distributed
centrally and peripherally.25 Their signaling is mediated primarily through the turnover of
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phosphatidyl inositol. They were initially and extensively characterized in the rat stomach
fundus where they triggered muscle contractions (hence, formerly known as 5-HT2F
receptors).27 They were also initially cloned from rat cDNA.34 These receptors are
encoded by the HTR2B gene.34 They are distributed peripherally in the stomach, intestine,
pulmonary smooth muscles, myocardium, and osteoblasts.34 In the rodent central
nervous system, they are distributed in the dorsal raphae nucleus, cerebellum, lateral
septum, dorsal hypothalamus, and amygdala.34 Functionally, 5-HT2B receptors are
involved in presynaptic regulation of serotonergic neurons, vasoconstriction, normal
cardiac development, and regulation of release of 5-HT from the serotonin transporter.34
Distribution of the receptors in humans is highly similar to that found in rodents.34
They are distributed in cardiac musculature and valves, lungs, peripheral tissues, liver,
kidneys, and prostate. Lower levels of expression are found in the cerebral cortex,
pancreas, and spleen.34 In humans, 5-HT2B receptors undertake functions such as CNS
regulation, digestion, normal cardiovascular development and repair. They are highly
expressed early in murine embryos with a peak in expression at 8.5 days, as it plays a
crucial role in neural crest and heart development.34 5-HT2B KO (knockout) mice exhibit
defects in the development of the heart and do not survive past mid-gestation.34 Mice that
do survive, reach adulthood with cardiomyopathy-like symptoms. Overall, the human
receptor is 80% homologous to the rat receptor.34
ii. Signal transduction of 5-HT2B receptors
Similar to 5-HT2A and 5-HT2C receptors, 5-HT2B receptors are coupled to Gαq protein and
increase intracellular levels of inositol phosphate (IP 3) and diacyl glycerol (DAG) (Figure
4).34 Furthermore, their stimulation activates the arachidonic acid pathway via
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phospohlipase A2 (PLA2), and a nitric oxide (NO) synthesis pathway via the C-terminal
PDZ type 1 motif.34 Stimulation of 5-HT2B receptors triggers intracellular cyclic guanosine
monophosphate (cGMP) production by activation of constitutive nitric oxide synthase
(cNOS) and inducible NOS (iNOS).34 NOS is also activate directly by calcium. Contraction
of rat fundus muscle is mediated through Ca2+ influx via calcium dependent channels and
activation of a phospholipase C (PLC)-stimulated increase in PIP2 hydrolysis.34
The receptor is also coupled to β-arrestin, which is activated in the presence of
agonists such as lysergic acid diethylamide (LSD) and ergotamine.11,12 This is induced by
changes in “trigger motifs” in GPCRs near the binding pocket to facilitate large scale
helical movements to cause minute changes in the spatial arrangement of residues of
each helix with respect to the residues in other helices. These residues are highly
conserved, known as “microswitches”.12
In a neuroendocrine serotonergic-differentiated teratocarcinoma cell line,
stimulation of the 5-HT2B receptor leads to activation of PLA2, followed by arachidonic
acid release, which stimulates reactive oxygen species (ROS) synthesis via NADPH
oxidase.34 Downstream signaling leads to high levels of TNF-α, resulting in oxidative
stress and neurodegeneration.34
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Figure 4. Downstream signaling effectors of 5-HT2B receptors. (DAG = diacylglycerol;
PDGFR = platelet derived growth factor receptor; PLA 2 = phospholipase A2; PLC =
phospholipase C; NADPH = nicotinamide adeninedinucleotide phosphate; IP3 = Inositol
triphosphate; ERK = extracellular signal-regulated kinase; ER = endoplasmic reticulum;
PI3K = phosphoinositide 3‐kinase; NFκB = nuclear factor κ‐light‐chain‐ enhancer of
activated B cells; TACE = tumor necrosis factor α converting enzyme; BNP = brain
natriuretic peptide; COX = cyclooxygenase; LOX = Lipooxygenase; Src = sarcoma protooncogene tyrosine-protein kinase.34

15

iii. Characteristics of 5-HT2B receptors
The h5-HT2B receptor consists of 402 amino acid residues. The recently published crystal
structure of a 5-HT2B receptor with LSD (PDB ID: 5TVN) has provided unique insight from
the previously published crystal structure with ergotamine (PDB ID: 4IB4).11,12 Due to the
smaller size of LSD in comparison to ergotamine, LSD exhibits a longer residence time
within the receptor and is seated deeper in the binding pocket compared to ergotamine.12
LSD acts as a partial agonist and ergotamine is a full agonist at the 5-HT2B receptor.12
However, both exhibit biased agonism in that they stimulate the β-arrestin pathway.12 The
crystal structure also revealed the ergoline ring systems adopt distinct binding poses with
respect to each other in the orthosteric binding site and that LSD never visited the
conformation that was obtained by the small molecule crystal structure published by
Baker et al. in 1972.37 Additionally, the EL2 portion of the receptor forms a “lid” over this
binding pocket, and the residue L209EL2 forms a hinge by forming hydrophobic
interactions with ring C of LSD.12 The engagement of this residue, as suggested by
mutagenesis studies, propagates β-arrestin signaling and has little to no effect on Gq
signaling.12
The abovementioned knowledge of 5-HT2B receptors will be vital in studying the
consequence of agonists and antagonists in disease states such as valvulopathy,
migraine, and irritable bowel syndrome.34
c) 5-HT2C receptors
5-HT2C receptors are widely distributed in the dopaminergic cell body regions of
the substantia nigra and ventral tegmental area and terminal projection areas of the
nucleus accumbens, striatum, and prefrontal cortex.38 This class of 5-HT2 receptors is
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positively coupled to Gq and activation results in phosphoinositidyl inositol turnover. Their
initial discovery was by finding receptors with high affinity to LSD and mesulergine, and
low affinity for ketanserin.39 However, due to their binding properties resembling 5-HT1A
and 5-HT1B receptors, more than 5-HT2 sites, they were initially named 5-HT1C
receptors.39 They were later discovered by molecular cloning of the cDNA to have a high
degree of homology to the 5-HT2 receptor and were later named 5-HT2C receptors.39
Activation of these receptors results in the suppression of appetite. This property of 5HT2C receptors was used to create the anti-obesity drug lorcaserin40 - a 5-HT2C receptor
agonist. Genetic evidence suggests that 5-HT2C receptors stimulate reward-related
behavior.39 5-HT2C receptor KO mice have shown evidence of producing obesity and a
proneness to seizure with more responsiveness to electrical stimulation.39 The
dopaminergic system is modulated by the signaling of 5-HT2C receptors in the
mesocorticolimbic system in the ventral tegmental area (VTA).40 The system is also
modulated by the constitutive activity of 5-HT2C receptors.41 The activity of 5-HT2C
receptors in the absence of ligand can be detected based on the PLC, and in most cases,
5-HT2C receptors can be ten times as active as 5-HT2A receptors.41 This phenomenon is
explained by the isomerization of receptors at different conformations and isoforms. 41 The
5-HT2C receptors are unique in the aspect of undergoing RNA editing that converts five
adenosine residues to inosine.41 The various isoforms of 5-HT2C receptors are attributed
to this RNA editing feature that produces a difference in three amino acids in the second
intracellular loop of the receptor.41 The changes can affect the activity of the receptor due
to less efficient G-protein coupling. Certain isoforms of 5-HT2C receptors have been linked
to depression and schizophrenia.40
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Furthermore, 5-HT2C receptors enhanced cocaine-induced elevations of dopamine
in the nucleus accumbens.40 The anorexigenic drug fenfluramine is also said to act via
the activation of 5-HT2C receptors by producing hypophagia, as evidenced by mice lacking
functional 5-HT2C receptors and the inability of fenfluramine to attenuate feeding. 42 In a
behavioral satiety sequence (BSS) test, fenfluramine was able to enhance satiety in
mice.42 In mice lacking these receptors, it was unable to produce the same effect.43 Other
studies have been conducted to show strong evidence of the involvement of 5-HT2C
receptors in controlling feeding behavior, amongst which was m-chlorophenylpiperazine
(mCPP) and trifluoromethylphenylpiperazine (TFMPP) - agonists at 5-HT2B/2C receptors
and antagonists at 5-HT2A receptors.42 Due to the distribution of 5-HT2C receptors in the
VTA, hypothalamus, and amygdala, the main areas associated with emotional regulation,
they are considered a potential target for the treatment of schizophrenia and depression. 42
5-HT2C receptors, as evidenced by the recently published crystal structure, exist
as a homodimer.44 The INI isoform of the 5-HT2C receptor crystal structure was
crystallized along with the agonist ergotamine and inverse agonist ritanserin.44 Prior
evidence was published by Herrick-Davis and co-workers that 5-HT2C receptors are found
in the choroid plexus epithelial cells.45 The signaling properties of homodimers were
investigated using ergotamine, a high affinity 5-HT2A/2B/2C receptor ligand.46 Although it is
debatable if the binding of ligands to one of both protomers of a dimeric complex is
necessary or sufficient for G-protein signaling, it is known that the second protomer does
not remain silent and plays a role in the signaling process. 45 The genetic polymorphism
of 5-HT2C receptors is associated with weight gain in patients on antipsychotic treatment.
Obesity and diabetes are thus a comorbidity in patients expressing this polymorphism.42
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3. Therapeutic agents and valvulopathy
a) Ergot derivatives – pergolide (1) and cabergoline (2) are potent agonists at 5-HT2B
receptors.47 It is, however, not a class effect seen in all ergolines (ergot derivatives)
(Figure 5). Bromocriptine and 8α-aminoergolines such as lisuride (3) and terguride (4)
lack agonist activity but are potent, silent antagonists at 5-HT2B receptors.48 Due to this
reason, pergolide (1) – a dopamine receptor agonist was used in the treatment of
Parkinson’s disease, but withdrawn from the market in 2007 for causing serious damage
to patients’ heart valves (mitral and tricuspid).5 Lisuride (3), interestingly, is an agonist at
5-HT2A and 5-HT2C receptors, but an antagonist at 5-HT2B receptors.48 This finding further
helped reinforce the idea that 5-HT2B receptor activation is necessary for causing
valvulopathy. A study conducted by Schade et al.49 investigated the involvement of other
dopaminergic agonists used to treat Parkinsonism (bromocriptine (5), cabergoline (2),
pergolide (1), pramipexole (6), and ropinirole (7)) also caused agonism of 5-HT2B
receptors. Pergolide (1) and cabergoline (2) were the only two molecules that caused
valvulopathy.49 Ergot derivatives such as ergotamine (8), dihydroergotamine (9), and
methysergide (10), used to treat migraine, also cause cardiac valvulopathy.49
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Pergolide (1)

Terguride (4)

Cabergoline (2)

Bromocriptine (5)

Lisuride (3)

Pramipexole (6)

Methysergide (10)

Ropinirole (7)
R1-R2 = -HC=C-Ergotamine (8)
R1-R2 = -H2C-CH- Dihydroergotamine (9)

Figure 5. Ergot and related derivatives examined for causing valvulopathy.
(1-10)
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b) Fenfluramine – The compounds associated with fenfluramine consist of both optical
isomers of fenfluramine (11), and the de-ethylated analog/metabolite, norfenfluramine
(12). They were initially prescribed for the treatment of obesity as a serotonin transporter
substrate/5-HT agonist due to their appetite suppressant pharmacological profile. 19
Fenfluramine (11) was initially introduced in the 1960’s in France and in the 1970’s in the
US. It was marketed under tradenames Pondimin ® (racemic mixture of fenfluramine),
Redux® (the S- isomer of fenfluramine aka dexfenfluramine), and in combination therapy
with phentermine as Fen-Phen®.6 Phentermine being a dopamine transporter releaser,
was shown to not be implicated in the valvular disease. 6 Norfenfluramine (12) isomers
have higher affinity and potency at 5-HT2B receptors than fenfluramine (11), making the
metabolite (Figure 6) with higher side effects than the drug.6 Approximately twenty years
later, it was withdrawn from the market for producing cardiac valvulopathy.3
Methylergonovine was found to be a less effective agonist than fenfluramine, yet it
produces a more severe form of valvulopathy.6

Metabolism

Fenfluramine (11)

Norfenfluramine (12)

Figure 6. Metabolism of fenfluramine (11) to produce the more potent metabolite
norfenfluramine (12).
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Valvulopathy from fenfluramine is caused in doses ≥ 60 mg/kg.50 Fenfluramine (11)
is under clinical trials for the treatment of epilepsy and Dravet syndrome (severe
myoclonic epilepsy of infancy).50 In lower doses (10 - 20 mg/kg), fenfluramine (11)
reduces epilepsy in infants and there has been no evidence of valvulopathy in the patients
although it is premature to conclude if fenfluramine causes valvulopathy at such low
doses.50
c) 5-HT – Serotonin (5-HT (13)) is the endogenous ligand of the 5-HT receptor class.
Serotonin syndrome caused by neuroendocrine tumors secreting high levels of serotonin
causes valvulopathy. In a study conducted by Elangbam et al.,51 subcutaneous
administration of 5-HT causes valvular thickening in SD rats. The study also highlights
the importance of the serotonin transporter and its inhibition, further exacerbating
valvulopathogenesis. However, the histological manifestation seen is different in
anorexigen valves and serotonin-selective reuptake inhibitors.51 5-HT (13) is a
tryptamine/indolealkylamine (14), however this effect is not seen with all tryptamines
since there is no evidence of other tryptamines causing valvulopathy. Hence, the question
arises, do all 5-HT2B receptor agonists cause valvulopathy? Certain ergolines, which
possess the basic indolealkylamine scaffold (Figure 7) cause valvulopathy but
tryptamines themselves are not known to be involved in causing it, possibly due to lack
of sufficient investigation. Most tryptamines are not used therapeutically and some are
primarily hallucinogenic in nature.
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C
A

5-HT (13)

Tryptamine/ indolealkylamine (14)

B

Ergoline (15)

Figure 7.
Ergoline (15) contains the indolealkylamine scaffold (14), yet
indolealkylamines (except for 5-HT (13)) have not been implicated in causing
valvulopathy.

d) Lorcaserin – Lorcaserin (16) (Figure 8) is a potent agonist at 5-HT2B receptors and is
used to treat obesity by acting as an agonist at 5-HT2C receptors.52 Due to its potency
(EC50 = 943 nM) and high affinity (Ki = 174 nM) for 5HT2B receptors,52 it was studied for potential to cause
cardiac valvulopathy in patients.53 A study conducted by
Thomsen et al.,52 revealed lorcaserin (16) possessed
Figure 8. Lorcaserin (16).
approximately 104-fold functional selectivity for 5-HT2C
over 5-HT2B receptors.

The Psychoactive Drug Screening program at the National Institute of Mental
Health has screened common therapeutic agents for agonist activity at 5-HT2B receptors
in the quest to identify agents causing valvulopathy.54 The study found 27 agents among
2200 drugs and drug-like compounds.54 Including the abovementioned compounds, there
were five compounds not previously identified as valvulopathogens that behaved as
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agonists at 5-HT2B receptors: guanfacine, oxymetazoline, quinidine, xylometazoline, and
fenoldopam.54 Guanfacine and quinidine were used to treat hypertension and arrhythmia,
respectively.54 Being prescribed for prolonged periods, guanfacine and quinidine were
scrutinized for their ability to induce valvulopathy.54 However, due to possessing a lower
potency at 5-HT2B receptors than serotonin and norfenfluramine, they were not pursued.54
Oxymetazoline, xylometazoline, and fenoldopam were of less concern since they were
prescribed for shorter time periods. Among the drugs tested was ropinirole (7), which was
a weak agonist (EC50 = 2570 nM) at 5-HT2B receptors. Four cases of patients undergoing
therapy with ropinirole (7) were reported with valvulopathy.55 However, since the number
of cases was not high enough to be statistically significant, it was not further pursued. 54
4. Drugs of abuse and valvulopathy
a) 3,4-Methylenedioxymethamphetamine (MDMA) (17) - aka ecstasy, is a recreational
Schedule I drug. In crystalline, powder form, it is referred to by its street name “Molly” .56
The use of MDMA (17) was most popular during the late 1990s and early 2000s. It acts
as an empathogen and produces its effects primarily by acting as a releaser at SERT.57
In addition, MDMA (17) also has affinity for the 5-HT1 and 5-HT2 class of receptors.58 In
a study conducted by Lyon et al.,69 MDMA was investigated for its affinity for 5-HT1 and
5-HT2 receptors, along with its stereoselectivity. The (R)-MDMA isomer was found to have
~ 4-fold higher affinity than the (S)-isomer.69 It was first synthesized by Merck in 1912 and
was later rediscovered to study its effects as a psychopharmacological agent by Shulgin
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*
MDMA (17)

MDA (18)

Figure 9. 3,4-Methylenedioxymethamphetamine (MDMA) (17) and its metabolite 3,4methylenedioxyamphetamine (MDA) (18).
and Nichols, in 1978.61 Years later, It was implicated in causing valvulopathy amongst
chronic

users.4,60 It

undergoes

metabolism

(Figure

9)

in

vivo

to

produce

methylenedioxyamphetamine (MDA)(18), a more potent valvulopathogen than MDMA.60
In vitro studies were conducted on cardiac valvular interstitial cells to study the activation
of 5-HT2B receptors.4 However, MDMA is gaining popularity yet again in studies
concerning the treatment of PTSD in war veterans, firefighters, and police officers who
do not respond to conventional methods of treatments. 62,63
A study conducted on 29 young adults using MDMA (17), blindly evaluated cardiac
function with echocardiography.60 Eight subjects taking MDMA (17) had abnormal

R = CH3 = (S)-MDMA (17a)

R = CH3 = (R)-MDMA (17b)

R = H = (S)-MDA (18a)

R = H = (R)-MDA (18b)
)

Figure 10. Enantiomers of MDMA (17) - (S)-MDMA (17a) and (R)-MDMA (17b) and
their metabolites – (S)-MDA (18a) and (R)-MDA (18b), respectively.
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echocardiographic results.60 Due to the prevalence of ecstasy use recreationally in young
adults, it is a health risk to chronic users.60 A typical dose of ecstasy (pill form) is 50-150
mg, and the second of 100 mg is usually taken after 3 hours, increasing the dosage to
nearly 150-250 mg per usage.57 In certain cases, MDMA is combined with other
psychoactive drugs (most commonly, LSD) – a term referred to as “candy flipping”.64
Therefore, in order to reduce the amount of exposure in patients receiving experimental
therapy, it is administered as a micro-dose.65 The patients experienced significantly lower
severity in PTSD symptoms following a twelve-month period of therapy.65
MDMA possesses a chiral center (Figure 9), the (S)-isomer (17a) (Figure 10) is a
more potent serotonin releaser, whereas (R)-MDMA (17b) is more potent at 5-HT2B
receptors (EC50 = 900 nM) than (S)-MDMA (17a) (EC50 = 6000 nM), possessing
approximately six-fold higher potency.4 The eutomer of MDA is not known, i.e., (R)-MDA
(18b) has an EC50 of 150 nM, its (S)-isomer (18a) has an EC50 of 100 nM, making them
roughly equipotent.60 In 1998, the X-ray crystal
structure of (S)-MDMA (17a) was determined by
Morimoto et al.15 The phenylisopropylamine
scaffold

of

MDMA

(17)

is

common

to

hallucinogenic amphetamine analogs. According

amine group are transposed with respect to each

Phenylisopropylamine
DOET (20)
scaffold 19; TMA (19a)
(R = OMe; R’ = NH2)
DOB - 19b (R= Br; R’ =
NH2)

other in comparison to other hallucinogenic

Figure 11. Structures of TMA (19a),
DOB (19b) and DOET (20).

to the study, the alpha-methyl group and the

phenylisopropylamines (19) (shown in Figure 11) 1-(2,4,5-trimethoxyphenyl)propan-2amine (TMA; 19a) and 1-(2,5-dimethoxy-4-ethylphenyl)propan-2-amine (DOET; 20).13
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The comparative differences may help determine the features necessary for high affinity
5-HT2B binding (as seen in DOB; 19b)) in order to study its pharmacological effects in
producing valvulopathy.

b) LSD – LSD (21), shown in Figure 12, is a hallucinogenic recreational drug. It belongs
to the ergoline class of compounds and is a synthetically derived drug, first synthesized
by Albert Hoffman in 1938 at the Sandoz company in Basel, Switzerland. 59 It became
popular in the 1970s in several experimental studies for the treatment of alcoholism,
anxiety, and depression.66 Its hallucinogenic effects are mediated due to its activity at the
5-HT2A receptor as shown by Glennon et al.67 LSD (21) possesses two chiral centers at
the 5- and 8-positions, and therefore exists as four optical isomers: (R, R), (R, S) aka isoLSD, (S, R) and (S, S). The (R, R) isomer is the most stable and possesses the highest
affinity for the 5-HT2 receptor class, while the other isomers are unstable and the 8position epimerizes back from the (S)-configuration to (R)-configuration under basic
conditions.68 Due to its high affinity at 5-HT2 receptor class, tritiated LSD is used as a
radioligand for affinity studies. It acts as a potent agonist at 5-HT2B receptors.10 There
have been no reports of cardiac valvulopathy caused by LSD (21). Perhaps, due to being
a potent agonist and recruiting beta-arrestin pathway faster than a low efficacy agonist.

8

D
5

C
A

B

Figure 12. (5R,8R)-Lysergic acid diethylamide (LSD) (21).
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The X-ray crystal structure of LSD (21) was first published by Baker et al. in 1972.37
The constrained ring systems of LSD (21) confers near planarity to the molecule with the
exception of the diethylamide side chain. The activity of LSD (21) was highly attributed to
its conformation. Thus, it was important to determine if the natural crystallographic
conformation is the bioactive conformation when binding to the 5-HT2A receptor. The
small molecule X-ray crystal structure was moderately predictive of the active state of
LSD. However, in 2017 LSD was co-crystallized with the 5-HT2B receptor that serves as
a suitable model for the 5-HT2A receptor.12 The co-crystal structure and molecular
dynamics simulations demonstrate LSD does not visit the conformation observed in the
small molecule crystal structure.12 This may be attributed to structural strain imposed by
the crystal formation that influences the conformation of the molecule.
5. Phenylisopropylamines: structure-activity relationships
In 1984, Glennon et al. proposed that classical hallucinogens produce their effects
by activating (agonists) 5-HT2A receptors.67 It has been established that hallucinogenic
phenylisopropylamines primarily act as agonists at 5-HT2 receptors, thus they qualify as
classical hallucinogens by mediating their effects through the agonism of 5-HT2A
receptors.67,70 They have varying degrees of selectivity at the three types of 5-HT
receptors. When substituted at 2- and 5-position of a phenylisopropylamine system (22),
the compounds are referred to as DOX compounds (Figure 13). Amongst hallucinogens,
the DOX series possess the highest affinity for 5-HT2 receptors.70 DOX compounds are
arylalkylamines, a class of widely studied hallucinogens. 70 DOI (19c) has been used to
characterize and study 5-HT receptors for radioligand binding studies and functional tests.
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19

Figure 13. Phenylisopropylamine (amphetamine) (22), and general scaffold of 4substituted 2,5-dimethoxyamphetamines (DOX compounds) (19) where R = I; R’ = NH2
for DOI (19c) R’ may be primary/secondary/tertiary amine.

With one chiral center in the isopropylamine chain, they are di- or tri-substituted,
typically with methoxy groups at 2- and 5-positions, and a variable substituent at the 4position on the phenyl ring. The affinity increases with mono-, di- and tri- substitution
(methoxylation).70 The 2,4,5-substitution pattern is deemed ideal for high hallucinogenic
activity.71
Structure-activity relationships have been previously established in the tests
conducted on rat fundus muscle, and other isolated tissue preparations. 70 Subsequent
studies utilized rat brain homogenates, and later, cloned human 5-HT2A receptors. The
general SAR derived from these systems is fairly consistent. The presence of an alphamethyl group contributes to the affinity of phenylisopropylamines, in comparison to
phenethylamines which have lower affinity. N,N-Dimethylation halves the affinity at 5-HT2
receptors.70 Addition of methyl group at the 4-position increases affinity, and no
appreciable increase in affinity is seen with a 4-ethyl substitution. In addition, the activity
of 4-substituted 2,5-dimethoxyphenylisopropylamines (19) exists as a continuum from
agonist to antagonist based on the nature of the 4-position group.70 The phenylpropyl
substituent at the 4-position was the first compound of the DOX class of compounds that
behaved as an antagonist, and these antagonists have a distinct structure affinity
29

relationship, as the methoxy substituents at 2- and 5- positions are less favorable than
2,3-,

3,5-,

and

2,6-positions.71

The

4-position

modulates

the

affinity

of

phenylisopropylamines for the 5-HT2A receptor, and a Hansch analysis of the substituents
of the series conducted in a previous study suggests an increase in affinity at 5-HT2
receptors with an increase in lipophilicity of the substituent at this position. 71 The high
affinity of the DOX series may be attributed to the multiple substitutions at the phenyl
ring.70 Substituents with less bulk behave as agonists and adopt a distinct binding pose
in contrast to antagonists which are bulkier and interact with more residues, thus
accessing the secondary binding pocket.72 Compounds with a bulky 4-position substituent
behave as antagonists and no longer require the features necessary for 5-HT2A binding,
for example, removal of the methoxy substituents is tolerated in phenethylamines with a
4-phenylpropylamine substituent.72

24

25

26

27

Figure 14. Structures of methoxy-constrained phenylisopropylamines.

The orientation of the methoxy groups is preferred to be planar, which serves as evidence
for the decreased affinity of the 2,4,5-trimethoxyamphetamine (TMA) (19a) in comparison
to the more constrained compounds (e.g. 25).73 In order to further study the orientation of
the two methoxy groups, constrained analogs of 2,5-dimethoxy-4-substituted compounds
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were prepared systematically (Figure 14), by first individually constraining the 2-position
and the 5-position methoxy group as seen in 24 and 25 respectively, and finally, both, to
provide benzodihydrofuran ring, seen in 26.73
The benzodihydrofuran ring constraining 5-position methoxy ring of DOB (19b) 25, showed an improvement in affinity to Ki = 3.1 nM in a rat prefrontal cortex preparation,
and the benzodihydrofuran ring constraining both methoxy groups yielded the ‘dragonfly’
analog of DOB (19b) (i.e., 26 where R = Br), which drastically improved the affinity to 0.48
nM in a cloned 5-HT2A receptor population.73
Aromatization of the dihydrofuran to furanyl rings resulted in 27, leading to potent
compounds (affinity and potency data not provided). Increasing the ring size of 25 to a
dihydropyran resulted only in a slight/insignificant lowering of affinity (Ki = 3.7 nM).73
However, the same structural changes did not produce the same effects in 3,4,5-methoxy
substituted compounds, indicating they may bind in a different manner. 73 There was no
apparent difference in affinity found in racemates of DOX related compounds upon alpha
methylation, however, in compounds such as DOB (19b), DOM and MDA (18), the R(-)enantiomer was the eutomer.67 Phenylisopropylamines and aminotetralins were
considered to be structurally similar to the ring C and D of ergolines. 73 The Rstereochemistry of the alpha methyl carbon in phenylisopropylamines and the 5-position
of LSD (21) was shown to be optimal for affinity at 5-HT2A receptors.73 These structural
similarities have prompted studies which compare the binding poses of LSD to DOX
series compounds.73 To explore the favorable conformations of the alkylamine chain,
cyclobutene analogs were prepared to identify if the extended chain is in the same plane
as found in LSD, or away from the plane of the ring.73 The phenylisopropylamines were
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found to adopt a conformation with the alkylamine chain away/perpendicular to the plane
of the benzene ring.
Binding modes: There has been statistically significant correlation of the binding of
phenylisopropylamines at 5-HT2A receptors, and 5-HT2B and 5-HT2C receptors.9 The
binding modes of DOB (19b) and DOI (19c) were initially studied in models of 5-HT2A
receptors by Parrish et al.,16 and Runyon et al.17 with a homology model constructed from
the bovine rhodopsin sequence. Subsequently, a β2 adrenergic receptor-based homology
model was published by Kanagarajadurai, et al.18 Since the 5-HT2A receptor serves as a
model for the 5-HT2B receptor and vice versa, previous models serve as a suitable
template to validate the docking results obtained with the 5-HT2B receptor. The model
proposed by Runyon, et al.,17 was based on the premise of two distinct binding sites - 1
and 2 for agonist and antagonists, respectively. Site 1 engages residues in helices TM3,
TM4, TM5, and TM6; and Site 2 – TM1, TM2, and TM7.17 Transmembrane helices TM3
(Asp1553.32, Ser1593.36) and TM6 (Trp3366.48, Phe3396.51) are in the subset of shared
between the two sites.17 Included in this model of agonist binding mode of the 5-HT2A
receptor with common agonists such as 5-HT, LSD and dopamine, (dopamine also being
an agonist at 5-HT2A receptor).17 The model of the 5-HT2A receptor with bovine rhodopsin
receptor as a template, proposed interactions that were seen with DOI (19c).17 As
predicted, compounds with small substituents as found in DOB (19b), adopt an agonistpreferred position engaging residues in Site 1.17 The 4-position substituent binds in the
interfacial region between TM5 and TM6. While addition of methyl and ethyl groups are
tolerated at the 4-position, the ethyl group is thought to displace the aromatic ring from its
initial site by 2.3 Å upon minimization.17 Bulky 4-position substituted compounds are
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oriented in a way as to access Site 2, adopting a more antagonist-like pose, as validated
by functional activity studies.17
Stereoisomers of DOB (19b), R(-)-DOB and S(+)-DOB, both have high affinity for
the 5-HT2A receptor, with the R(-) isomer showing ~7-fold higher affinity (Ki = 0.29 nM)
than the S(+)-isomer (Ki = 1.9 nM).17 Modeling studies conducted on the isomers of DOB
(19b) in the 5-HT2A receptor by Parrish et al.,16 asserts the differential orientation of the
residues lining the agonist binding pocket. The models published by Parrish et al.16 and
Runyon et al.17 differ in the π-stacked interaction between Phe3406.52 and Phe2435.47,
which may be crucial for maintaining the orientation of the transmembrane helices.
Mutation of Phe3406.52 in 5-HT2A receptors abolished affinity for DOX compounds,
indicating the importance of aromatic interactions in their binding. 16 The aspargine
(Asn3446.55) on helix 6 is crucial for the binding of DOB (19b) as evidenced by its
increased affinity for 5-HT2 receptors, as it is highly conserved in 5-HT2 receptors as
opposed to 5-HT1 receptors.17
6. DOB/DOI and their interactions observed in 5-HT2A receptor models
a. Parrish model
The model proposed by Parrish et al. compares the binding of the (R)- and (S)isomers of DOB (19b) within the 5-HT2A receptor binding pocket.16 In conjunction with
functional activity studies indicating the (R)-isomer to have higher affinity and potency,
the model examines the interactions with key residues found in the agonist binding
pocket: Phe2405.44, Phe2435.47, Phe2445.48, and Phe3406.52, and Ser2395.43.16 The
orientation of Ser2395.43 is significantly altered for both enantiomers.16 Phe2435.47 is
displaced in the (S)-isomer-docked receptor, while the 4-substituent of the (R)-isomer
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forms a hydrophobic interaction with the residue.16 The alpha methyl group undergoes
van der Waals interactions and the aromatic ring, an edge to face interaction with
Phe3406.52 which forms a tight association between the ligand and the residue. 6 The
residues Ser2395.43, Phe2435.47 and Phe3406.52 show different orientations when the (S)enantiomer binds but not with the (R)-enantiomer.16 Phe3396.51 on the other hand, shows
no perturbation in the docked ligand models and is supported by mutagenesis data as not
being strictly interacting with small molecule agonists.16

b. Runyon model
The 4-bromo substituent in DOB (19b) is oriented between TM5 and TM6.17 The
2-methoxy group accepts a hydrogen bond from N3436.55.17 The 5-methoxy group is near
Ser1593.36, Thr1603.37, and Ser2425.46, and the methyl group of 5-methoxy and W3366.48.17
Other aromatic interactions are seen with Phe2435.47, Phe3396.51, and Phe3406.52 (Figure
15). There is no H-bonding residue for the small 4-position substituents in the binding
pose adopted by DOX compounds.17 Larger 4-position substituents were found to be
folded onto the ligands aromatic ring and the aromatic ring is displaced towards TM4. 17
Antagonists of the DOX compounds place the phenyl ring between Asp1553.32 and
Val3667.39. This pose is stabilized in the binding site through H-bonding of DOX amine
moiety with Asp1553.32 and Ser1593.36, and the 5-methoxy group is stabilized with
Trp1513.28 and Ser226x12.49, although they are not considered ideal.17 The large
substituents are oriented towards Site 2.17
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Figure 15. Model of (R)-DOI and 4-phenylpropyl substituted DOX compound
docked in 5-HT2A receptor published by Runyon et al.17
The model constructed by Runyon et al.17 presents a π-stacked interaction between
F3406.52 and F2435.47. The validity of the model is based on the rotameric angle (χ1) of
the conserved residues Trp3366.48 and Phe3406.52 in the aromatic box, which are a part
of the rotameric “toggle switch”.17 This switch is also known as an “ionic lock” found in
rhodopsin-family GPCRs that has been proposed to link the cytoplasmic ends of TM3 and
TM6.74 Disruption of the lock is necessary but not sufficient for activation of the GPCRs,
since partial agonists were as effective as full agonists in disrupting the lock. 75 The torsion
angle of the residues with respect to the “proline kink” found in TM6, is responsible for the
distance between the intracellular ends of TM3 and TM6 which forms the toggle switch.17
The proline kink is a bend or kink found in helices of proteins and often plays a functional
role.75 At these kinks, the helices change direction and the hydrogen bonding pattern is
broken.75 They are identified by specifying an upper limit for differences in the angle of
the helical axis of two sets of a specific number of residues (depending upon the platform),
and annotating the residues which exceed the upper limit.75 The rotameric angle (χ1) for
validation of the model is trans for the two residues, which was previously reported. 17
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c. Kanagarajadurai model
Kanagarajadurai et al.18 developed a model of the 5-HT2A receptor emplyoing the
β2 adrenergic receptor as a template. This model revealed a set of residues that were
specific to 5-HT2A receptors that aids in distinguishing it from other 5-HT2 receptors. The
docking study was conducted on endogenous ligands – 5-HT and dopamine and agonists
– DOI (19c) and LSD, along with inverse agonists – clozapine and risperidone, and
antagonists – ketanserin and haloperidol.18 The study, was validated with mutagenesis
experiments where the key residue Ser159 was predicted to be vital in anchoring the
protonated amine of serotonin and other ligands.18 Mutation of the residue reduced the
affinity by 17.6-fold for serotonin and N,N-dimethyl-5-HT.18 Mutation of Y370 diminishes
affinity for serotonin and DOM but not for α-methyl-5-HT, further indicating a different
binding mode for serotonin and α-methyl-5-HT, suggesting that the α-methyl group
causes a difference in binding mode of tryptamines. Human 5-HT2A share 43% homology
with 5-HT2B receptors and 54% with 5-HT2C receptors.18 The docked DOI (19c) was able
to form a single cluster.18 The model indicates interactions with TM3, TM5, TM6, TM7,
ECL2 and ECL3.18 The residues common to DOI (19c) and LSD are Ser239, Ser159,
Asp231, Phe339, Phe340, Val235 and Gly238.18 S239 is necessary for the binding of DOI
(19c) as evidenced in mutagenesis but it is unclear if it may be due to secondary
intramolecular interactions and if it may be necessary to create an activated receptor. 18
Summarized below (Table 1) is a comparison of the three models. Due to several
confounding factors such as a difference in templates and the small size of the molecules
in comparison to the binding pocket, there are differences found in the models proposed
by the three groups.
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-

Isopropyl
chain
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S2395.43
F2435.47

-

4-Position
substituent

-

Phenyl ring F3406.52

5-Methoxy
group

2-Methoxy
group

F3406.52

-

Amine

-Methyl
group

Residues
(Parrish
model,
2005)

Substituent
s of DOX
molecule

Hydrophobic

F2435.47

-

Hydrophobic
Edge-to-face
Hydrophobic

Hydrophobic
Hydrophobic
H-bond
Hydrophobic

Hydrophobic

N3436.55

W1513.28
S226X12.49
S2425.46
W3666.48

I1523.29

van der
Waals

V1563.33

I1523.29

F3406.52

Type of
interaction

D1553.32
S1593.36

Residues
(Runyon
model,
2008)

Edge-to-face F2435.47
W3366.48
F3406.52

Not
mentioned

-

van der
Waals

-

-

Type of
interaction

F339

L229
F3406.52

S1593.36

N3436.55

-

V235
G238
S239

D231

Residues
(Kanagarajadurai model,
2009)

Hydrophobic

Hydrophobic
Edge-to-face

H-bond

Not
mentioned/
van der
Waals

-

Hydrophobic
Hydrophobic
Not
mentioned

H-bond

Type of
interaction

Table 1. Comparison of prior models of DOX compounds docked in the 5-HT2A
receptor in chronological order

III.

Specific aims and rationale

Seventeen phenylisopropylamines of the DOX series were synthesized in the
Glennon laboratory,9 and tested at the three subtypes of 5-HT2 receptors (5-HT2A, 5-HT2B,
and 5-HT2C). These compounds were also compared for their binding affinity at 5-HT2C
vs 5-HT2A, 5-HT2B vs 5-HT2A, and 5-HT2B vs 5-HT2C receptors.9 Cloned human 5-HT2A, 5HT2B, and 5-HT2C receptors, and rat 5-HT2B receptors were used as expression systems.9
The compounds varied, primarily, in the 4-position substituent, which is a vital modulator
of affinity.9 Comparison of the receptor affinities showed a strong positive correlation
between 5-HT2A and 5-HT2C receptor affinities (r = 0.93), and 5-HT2A and 5-HT2B receptor
affinities (r = 0.92).9 The slope for 5-HT2C vs 5-HT2A receptor (0.93) affinity was higher
than that observed for 5-HT2B vs 5-HT2A affinity (0.53), indicating a less direct relationship
of affinity for 5-HT2B vs 5-HT2A receptors.9 This suggests a difference in the binding
pockets of the two receptors.9
The availability of the X-ray crystal structure of the 5-HT2B receptor12 will serve as
a tool for studying the interactions of the abovementioned phenylisopropylamines and
serve as a point of comparison for the previously published 5-HT2A receptor models with
DOB (19b)/DOI (19c).16-18 Although the functional activity of the phenylisopropylamines
at 5-HT2B receptors is not entirely known, extrapolations with the data available at 5-HT2A
receptors may serve in predicting the functional activities. The binding mode of
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phenylisopropylamine 5-HT2A agonists is distinct from that observed for antagonists in
that the bulkier substituents access a secondary binding pocket and thus orients the
phenyl ring and the 2,5-dimethoxy substituents differently.17 If similarities are found in the
binding modes at both receptor models, an SAR can be developed for 5-HT2B agonists
for this class of compounds.
Since the SAR of phenylisopropylamine 5-HT2A receptor agonists has been well
established, the strong positive correlation in the affinities at 5-HT2B receptors vs 5-HT2A
receptors serves as a stepping stone to develop the SAR of 5-HT2B receptor ligands of
the phenylisopropylamine class.9 Included in this class of 5-HT2B agents, are also
fenfluramine

(11),

norfenfluramine

(12),

MDMA

(17)

and

MDA

(18)–known

valvulopathogenic agents at the commonly used dosage. Therefore, quantitative
structure-activity relationship (QSAR) studies may serve as a useful tool to recognize the
nature of ligands and their substitution pattern for high affinity at these receptors.
The rank order of selectivity of phenylisopropylamines is 5-HT2A > 5-HT2B > 5HT2C.10 In contrast, (R)-fenfluramine, which possesses a phenylisopropylamine scaffold
without the 2,4,5-substitution pattern, has about 2-fold higher selectivity for 5-HT2B
receptors in comparison with the 5-HT2A receptors.76 The rank order of affinity of
fenfluramine and norfenfluramine isomers, as shown in Table 2, depicts the selectivity,
where (S)-fenfluramine differs from (R)-fenfluramine in its rank order of affinity, and the
norfenfluramine isomers are of the same order, with their highest affinity for 5-HT2C
receptors.76 In general, (R)-norfenfluramine binds at all three receptor populations with
twice the affinity of (S)-norfenfluramine.
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Table 2. Affinities of fenfluramines and norfenfluramines at the three subtypes of 5-HT2
receptors.76

Receptor

(S)-

(R)-

(R)-

(S)-

Fenfluramine

Fenfluramine

Norfenfluramine

Norfenfluramine

Ki (nM) ± S.E.M

Ki (nM) ± S.E.M

Ki (nM) ± S.E.M

Ki (nM) ± S.E.M

5-HT2A

2470 ± 240

1430 ± 330

187 ± 10

267 ± 16

5-HT2B

3920 ± 830

680 ± 16

56 ± 19

99 ± 12

5-HT2C

2080 ± 480

1620 ± 340

27 ± 7

65 ± 23

2B > 2C/2A

2C > 2B > 2A

Order
(5-HT)

2C~2A> 2B
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2C > 2B > 2A

The specific aims of the current project are:
1. To conduct 3D-QSAR studies on phenylisopropylamines to determine the
nature of substituents that confer high affinity.
Approach:
-

Perform a comparative molecular field analysis (CoMFA) and/or comparative
molecular similarity indices analysis (CoMSIA).

2. To study the interactions of the phenylisopropylamines with the 5-HT2B
receptor.
Approach:
-

Dock the phenylisopropylamines in the crystal structure of the receptor and
study their binding poses.

-

Perform HINT (Hydropathic INTeraction) analysis to determine the quality
of the model generated based on the HINT score obtained.

The models generated may provide insight on the functional activity of the compounds,
based on difference in binding poses observed in agonistic vs. antagonistic
phenylisopropylamines at the 5-HT2A receptor.
An indirect goal of these studies is to formulate SAR for the binding of
phenylisopropylamines at 5-HT2B receptors. To date, only a few phenylisopropylamines
have been shown to bind at 5-HT2B receptors (e.g., those shown later in Figure 3). And
none of them has been examined for their valvulopathogenic action. Some
phenylisopropylamines

(e.g.,

MDMA

and

norfenfluramine)

are

recognized

valvulopathogens, but to date, no 5-HT2B serotonin receptor SAR is available.
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III.

Results and discussion

GOAL 1. To conduct 3D-QSAR studies on phenylisopropylamines to
determine the nature of substituents that confer high affinity.

The key step in conducting a 3D-QSAR study using CoMFA is a sufficiently large data
set of approximately 20 molecules. Variation in substituents are made usually in
preferably one, or two positions on a common scaffold. A CoMFA may be conducted
on affinity data (Ki) or on potency (IC50/EC50) values (Table 3).
Table 3. Binding affinities of phenylisopropylamines (n = 17) at human 5-HT2B
receptors with two known agonists (blue).9, 10

5-HT2B Ki, nM

5-HT2B

Functional

pKi

activity

R

R’

19a

-OCH3

-NH2

TMA

307.0 (21)

6.51

NAa

19b

-Br

-NH2

DOB

26.9 (4)

7.57

Agonist

19c

-I

-NH2

DOI

20.0 (3)

7.70

Agonist

Name

(±SEM)
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19d

-H

-NH2

DMA

1039.0 (143)

5.98

NA

19e

-F

-NH2

DOF

227.0 (15)

6.64

NA

19f

-Cl

-NH2

DOC

31.8 (2)

7.50

NA

19g

-OC2H5

-NH2

MEM

763.0 (54)

6.12

NA

19h

-COCH3

-NH2

DOAC

313.0 (27)

6.50

NA

19i

-NO2

-NH2

DON

166.0 (28)

6.78

NA

19j

-CN

-NH2

DOCN

774.0 (46)

6.11

NA

19k

-nC3H7

-NH2

DOPR

54.4 (10)

7.26

NA

19l

-nC6H13

-NH2

DOHx

30.3 (12)

7.52

NA

-tC4H9

-NH2

DOTB

24.6 (6)

7.61

NA

-CH2ɸ

-NH2

DOBZ

35.0 (3)

7.46

NA

19o.

-Br

-N(CH3)

M-154

341.0 (49)

6.47

NA

19p.

-Br

-NH-C3H7

D-367

521.0 (6)

6.28

NA

19q.

-Br

-N+(CH3)3

QDOB

>10,000

NA

-

19m
19.

aNA:

Not applicable since no studies were conducted.
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1. CoMFA and CoMSIA studies on 5-HT2B receptor affinities
By using the pKi values of these ligands at 5-HT2B receptors (Table 3), a 3D-QSAR
study (CoMFA and CoMSIA) was conducted using Sybyl X2.1.1. CoMFA assesses the
interactions of aset of molecules with an electrostatic grid to determine the steric and
electrostatic substituents necessary for the affinity of a compound, whereas CoMSIA
assesses similarities based on five criteria: steric, electrostatic, hydrophobic, hydrogenbond donor and hydrogen-bond acceptor fields amongst the compounds that may confer
affinity. The key step in conducting CoMFA was to obtain a proper alignment of three noncolinear points common to all the structures within the series. Upon attempting multiple
points of alignments, the aromatic centroid, C5 of the benzene ring, and the nitrogen atom
of the amine were found to be most suitable for common points of substitutions on the
phenyl ring amongst the series of compounds (Figure 16A and 16B).
The initial CoMFA study including only DOX compounds (n = 16; QDOB (19q) has
very low affinity Ki > 10,000 nM, hence not included) with 5-HT2B receptor affinities yielded
a q2 value of -0.118 with a standard error of prediction of 0.893 with the optimal number
of components being 1. For CoMSIA, a q2 value of 0.612 was obtained with the standard
error of prediction being 0.453. Further PLS analyses were conducted by the removal of
the field having the lowest contribution, the optimal value was q 2 = 0.669 upon removal
of electrostatic, donor and acceptor fields, leaving only steric and hydrophobic fields.
Certain fields may be excluded if their contribution to the q2 value is under 15%.
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A

B

2

1
6

3

Aromatic
centroid

4

5

Figure 16. (A) General structure of DOX compounds (19), including points of alignment
(blue). (B) Aligned compounds using the “Fit atom” command in Sybyl X2.1.1 (n = 22),
includes the sixteen DOX compounds from the initial study, R- and S- isomers of MDA,
and R- and S-isomers of norfenfluramine and fenfluramine.
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A negative q2 value is a sign of no model and is mainly due to a narrow range of affinity
values, i.e., when the standard error of prediction (PRESS) is larger than the standard
deviation.77 The Ki values at 5-HT2B receptors represent a 50-fold range.9 Figure 17
provides a representation of the distribution of pKi values at the 5-HT2B receptor.

D367
6.28
SFEN
5.29

MEM
6.12

RFEN
5.24

DMA
5.98

TMA
6.51
DOF
6.64
DOAC
6.50

RNF
7.32

DOHx
7.52

5.5

MDA
7.00

6.5

Affinity values at 5-HT2B
receptors
(n = 22)

RFEN = (R)- Fenfluramine
SFEN = (S)-Fenfluramine
RNF = (R)-Norfenfluramine
SNF = (S)-Norfenfluramine

7.46 DOTB
7.61
DOPR
DOC
7.26

DOCN M154
DON
6.11 6.47 6.78

6

SNF
7.95

DOI
DOBZ 7.70

7.50

MDMA
6.30

5

DOB
7.57

7

7.5

8

8.5

9

9.5

Figure 17. Distribution of pKi values of phenylisopropylamines at 5-HT2B receptors. Data
in red represent the initial study (i.e., n = 16).

The value for q2 did not improve beyond negative values for CoMFA after reducing column
filtering or modifying the region file to include smaller step sizes. Thus, in order to increase
the diversity of the dataset, the R and S isomers of the well-known 5-HT2B ligands
fenfluramine (11) and norfenfluramine (12) were added (n = 20).6 The CoMFA on 5-HT2B
with fenfluramine (11) and norfenfluramine (12) isomers, improved the q2 value to 0.240,
which was not the case with CoMSIA (q2 = 0.190).
Operating on the same principle of increasing diversity, known ligands of the 5-HT2B
receptor MDA (18) and MDMA (17) were added to the data set (n = 22). A major caveat
to this addition is the lack of availability of individual enantiomeric affinities, therefore R
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isomers were used in the CoMFA study, with the affinities of the racemic mixtures. The
q2 value for CoMFA was 0.325, while the CoMSIA model was not as robust, yielding q2 =
0.181. This CoMSIA model was however fine-tuned to obtain a q2 of 0.54 by excluding
the fields that had the lowest contribution. By doing so, steric and hydrophobic fields were
the highest contributors, operating at a 0.68:0.32 ratio. The CoMSIA representation is
displayed in Figure 18 with the yellow and white areas representing favorable and
unfavorable contour maps (80:20 ratio of favorable: unfavorable visualization) for
hydrophobic substituents, and the blue and red contour map displaying favorable and
unfavorable areas for steric bulk, respectively (Figure 18) This figure suggests
hydrophobicity to be favorable at the 4- position, whereas it is not well tolerated at the
amine, which can be determined from a cursory examination of the trend of the pKi values
in the data set. However, the q2 value provides validation of this trend, suggesting better
predictive power.
According to Cramer,78 on the basis of CoMFA investigation of a steroid data set,
the presence of constrained analogs is said to improve the predictivity of the model due
to a known favorable conformation of the compound. Hence, (+) (5R,8R) LSD (21), the
5-HT2B receptor co-crystal structure of which was recently reported, was added to this
data set to determine if it might improve the model (pKi = 8.43).12 This brought about little
improvement in the result (CoMFA q2 = -0.334; CoMSIA q2 = 0.279) (n = 23). In order to
align the structures to more closely resemble LSD (21), the energy minimized structures
of the data set were aligned with the crystal structure as the template using both atom fit
as well as multifit approaches.

47

Figure 18. 5-HT2B receptor (n = 16) hydrophobic (left) and steric (right) CoMSIA fields of
DOI (19c). For the hydrophobic field, yellow and white areas indicate favorable and
unfavorable substitutions; for the steric field, blue and red areas indicate favorable and
unfavorable areas, respectively.
The above data are entirely based on atom fit, however multifit served little
purpose, as the difference in energies between the energy-minimized structures and
multifit modified structures was roughly 5 kcal/mol for the entire data set and the CoMFA
q2 was -0.350. Since the purpose of this modification was to mimic the structure of LSD
(21) with phenylisopropylamines, the spring constant was modified to its reasonable limit
(20 kcal/molÅ2), and the desired conformer could not be constructed. The conformer of
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DOB (19b) that mimics LSD exists at 69.45 kcal/mol according to the top ranking
(ChemPLP score) docking solution in GOLD v5.4, as opposed to its lowest energy
conformer at 35.90 kcal/mol. A CoMFA study on the energy minimized structure of LSD
was also conducted (data not included), but led to little improvement of the model.
There are certain trends observed in the affinity values of the compounds at the 5HT2B receptor, which on comparison with 5-HT2A receptor affinities, provide clues about
the differences in the binding pockets of both receptors. For example, compounds with
increased 4-position chain length, (DOHx (19l), DOBZ (19n), and DOPR (19k)) display a
>50-fold increase in 5-HT2A receptor affinity relative to DMA (19d), whereas this is not the
case with 5-HT2B receptor affinity.9 This is strongly evident in the case of DOHx (19l),
where the affinity is 303 times greater at 5-HT2A receptors than at 5-HT2B receptors.
1. CoMFA study on 5-HT2A receptor affinities
Since a potential reason for low predictivity was the narrow range of affinity values
at 5-HT2B receptors, CoMFA studies on the same compounds with affinity values at 5HT2A receptors (Table 4) were conducted as a comparative study, and yielded a q2 of
0.398 (quaternary DOB or QDOB (19q) not included, n = 16) with a standard error of
1.027, and the CoMSIA study, q2 = 0.606.
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Table 4. Binding affinities of phenylisopropylamines (n = 17) at human 5-HT2A
receptors; 8 are known to be agonists, 3 partial agonists and one antagonist (blue, light
blue and red respectively).9,

R

R’

Name

5-HT2A Ki,
nM (±SEM)

5-HT2A

Functional

pKi

activity

19a

-OCH3

-NH2

TMA

57.9 (3.3)

7.24 Agonist88

19b

-Br

-NH2

DOB

0.6 (0.1)

9.22 Agonist87

19c

-I

-NH2

DOI

0.7 (0.006)

9.15 Agonist5.5,87

19d

-H

-NH2

DMA

211.0 (15)

19e

-F

-NH2

DOF

41.7 (1.8)

19f

-Cl

-NH2

DOC

1.4 (0.04)

19g

-OC2H5

-NH2

MEM

73.0 (10.0)

7.14 Agonist93

19

-COCH3

DOAC

80.5 (12.1)

7.09 NAa

19i

-NO2

-NH2
-NH2

DON
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5.5 (0.6)

6.68 Partial agonist87
7.38 Agonist
8.85

Agonist89

8.26 Partial agonist87

aNA:

19j

-CN

-NH2

DOCN

45.7 (0.9)

7.34 NA

19k

-nC3H7

-NH2

DOPR

0.9 (0.01)

9.05 Agonist88-90

19l

-nC6H13

-NH2

DOHx

0.1 (0.03)

10

19m

-tC4H9

-NH2

DOTB

3.7 (0.2)

8.43 Partial agonist91

19n

-CH2ɸ

-NH2

DOBZ

0.4 (0.08)

9.40 Antagonist92

19o

-Br

-N(CH3)

M-154

94.2 (6.8)

7.03 NA

19p

-Br

-NH-C3H7 D-367

88.5 (5.8)

7.05 NA

19q

-Br

-N+(CH3)3 QDOB

2155 (56)

5.67 NA

Antagonist92

Not applicable since no studies were conducted.
The positive and robust q2 value might be due to not only a higher range (2,110-

fold) of affinity values, but also a good dispersion of pKi values over 3.32 log units
(QDOB not included, n = 17). Figure 19 displays the contour map obtained for 5-HT2A
receptor CoMFA, the red areas indicating unfavorable substitution at 3-position may be
explained by the addition of fenfluramine and norfenfluramine isomers to the data set.
The best CoMSIA model (Figure 20) indicates that hydrophobic substituents at 3position detracts from affinity, and similar to 5-HT2B receptors, a large (steric)
hydrophobic substituent at 4-position is favorable. Any substitutions on the primary amine
are not well tolerated at both 5-HT2A and 5-HT2B receptors.
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Figure 19. 5-HT2A receptor CoMFA (n = 20) contour map. Blue and red areas represent
favorable and unfavorable areas for electron withdrawing substituents, respectively.
Green and yellow areas represent favorable and unfavorable areas for steric bulk,
respectively.

Figure 20. 5-HT2A receptor (n = 20) hydrophobic (left) and steric (right) CoMSIA fields of
DOI (19c). For the hydrophobic field, yellow and white areas indicate favorable and
unfavorable substitutions; for the steric field, blue and red areas indicate favorable and
unfavorable areas, respectively.

52

Figure 21 provides a visual representation of the distribution of pKi values at 5HT2A receptors. To emphasize the importance of the range of pKi values, adding QDOB
to the 5-HT2A CoMFA study barely showed appreciable improvement of the model (q2 =
0.402 for CoMFA and q2 = 0.302 for CoMSIA), however, addition of other well-known 5HT2B receptor ligands that also possess affinity for 5-HT2A receptors showed a vast
improvement of the 5-HT2A model.
Affinity values at 5-HT2A
receptors

MEM
7.14

(n = 21)

DOCN
DOAC
7.34
7.09
D367
7.05

RFEN SNF
5.62 5.81
SFEN
4.95

5

RNF
5.41 QDOB
5.67

5.5

DMA
6.67

6

6.5

M154
7.02

7

DOB
9.22

TMA
7.24

DOTB
8.43

DOF
7.38

8

DOC
8.85

DOB z
9.39

DOHx
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DOPR
9.04
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8.26

7.5

DOI
9.15

8.5

9

9.5

Figure 21. Distribution of pKi values of phenylisopropylamines at 5-HT2A receptors.
DOX compounds are represented by red lines, fenfluramine and norfenfluramine
isomers, grey lines.
The ligands used were the R and S isomers of fenfluramine (11), and
norfenfluramine (12).6 By adding these four compounds (n=21), the q2 value for CoMFA
increased to 0.685 with a standard error of prediction of 0.941 and the optimal number of
components was 4. The CoMSIA, results also improved significantly, yielding a q2 of
0.799.
Thus, with an improved distribution along with a fairly broad range of pKi values, a
good model was obtained, as evidenced by a comparative study of 5-HT2B versus 5-HT2A
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affinity values. This is consistent with the literature on CoMFA studies that specifies that
a good range and spread of values is recommended (typically 2.5 - 3 log units).79-81 Thus,
due likely to the low range of affinity values at the 5-HT2B receptor, the CoMFA studies
were unsuccessful. However, the CoMSIA study, although yielding 0.61 in q2 value, did
not withstand validation when divided into the training set and test set. Validation was
performed by dividing the 16 compounds (Table 3 minus 19q) into a training set of 12
compounds (19d – 19j, 19l - 19p) and a test set of 4 compounds (19a – 19c, 19k) after
trial-and-error of modifying the training set and consequently, the test set, a q2 value of
0.48 was obtained and the standard error of prediction was 0.216. Thus, the 5-HT2B
CoMSIA study was internally validated, but could not be externally validated. This leads
to the conclusion that having a good distribution and range of affinity values is necessary
for obtaining a good CoMFA/CoMSIA model.
Provided below are the results of the CoMFA and CoMSIA studies conducted on
5-HT2A and 5-HT2B receptor affinities (Table 5).
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Table 5. CoMFA and CoMSIA summarized.

Model
No.

No. of
compounds

Compounds
added

1.

n = 16

None

2.

n = 20

3.

CoMFA
q2
(5-HT2B)

CoMSIA
q2
(5-HT2B)

CoMFA
q2
(5-HT2A)

CoMSIA
q2
(5-HT2A)

−0.209

0.612

0.398

0.606

RFEN, RNF,
SFEN, SNFa

0.240

0.190

0.769

0.841

n = 17

QDOB

−

−

0.402

0.302

4.

n = 21

QDOB,
RFEN, RNF,
SFEN, SNF

−

−

0.685

0.799

5.

n = 22

RFEN, RNF,
SFEN, SNF,
MDA,
MDMAb

0.325

0.181

−

−

6.

n = 23

LSD, RFEN,
RNF, SFEN,
SNF, MDA,
MDMA

-0.334

0.279

a RFEN

-

= (R)-Fenfluramine; SFEN = (S)-Fenfluramine; RNF = (R)-Norfenfluramine;

SNF = (S)-Norfenfluramine
b

MDA = Methylenedioxyamphetamine; MDMA = Methylenedioxymethamphetamine
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The 5-HT2A receptor CoMSIA model yielding q2 = 0.841 (Row 2 in Table 5) was
validated by dividing the data set of 20 compounds into a training set and test set of 15
compounds (19a, 19c – 19e, 19g-19j, SFEN (11a), and RFEN (11b)) (75%) and 5
compounds (19b, 19f, and 19k, SNF (12a) and RNF (12b)) (25%), respectively. The q2
value of this model was 0.682 when the acceptor field was dropped. In order to test the
influence of choice of training set on the q2 value, DOB (19d) was replaced with DOF
(19e) in the training set to increase the diversity of the steric factor, i.e., since the fluorine
atom (in DOF) is similar in size to the hydrogen atom (DMA (19d)), which was already
included in the training set, bromine was used as a suitable replacement as it is also a
halogen, except with a larger radius. This replacement increased the q2 value
conservatively by 0.004 (= 0.680), and was accepted as the final model. The test set of 5
compounds for this model included 19e, 19f, 19k, 12a and 12b. The choice of training set
(remainder of the compounds, n = 15) was aimed at including the most diversity and
redundancies to provide a good template of lipophilic, electrophilic, and steric properties.
The abovementioned compounds of the test set are all replicated by similar compounds
in the training set, therefore eliminating novel compounds. The standard error of estimate
was 0.43, and the correlation coefficient (R2 value) was 0.931. The average of the
residuals was found to be 0.417. The training set was modified to be reduced to 14
compounds (19a- 19c, 19d, 19h-19j, 19l-19p, 11a, and 11b) and the test set increased
to 6 compounds (19e-19g, 19k 12a, 12b). As may have been expected, this reduced the
q2 value to 0.569, indicating the requirement for a more diverse and larger training set.
The higher predictive power of CoMSIA over CoMFA is expected as there are similar
(propyl, tert-butyl, hexyl, benzyl substituted) compounds in the data set and no
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compounds with electron donating, or hydrophilic substitutions (for example, -OH, -NH2),
which may be required to gain clarity over the changing patterns of affinity when exploring
chemical

space.

On

the

other

hand,

a

CoMFA

study

on

hallucinogenic

phenylsopropylamines has been conducted in the past using Mescaline Units for
biological activity at 5-HT2A receptors.82 The results of the study are consistent with the
current findings that bulky substituents at the 4-position are favorable for activity, as was
with the finding by Dommelsmith, et al.83 This can be extrapolated to its affinity since high
affinity is proportional to efficacy in 5-HT2A ligands.84 This is attributed to the presence of
G-protein coupled receptors in a high affinity state and a low affinity state, and agonists
are capable of selectively binding to, or stabilizing the active conformation of the
receptor.84 However, since DOTB (19m) and DOHx (19l) have high affinity, this assertion
is contradicted as they act as partial agonists/antagonists and antagonists typically bind
with high affinity to both states.91,92 Additionally, the study by Seggel et al.71 and a later
published 3D-QSAR study by Zhang et al.82 indicate the presence of an electron
withdrawing substituent at the 4-position shows strong hallucinogenic activity (i.e., DOB
(19b), DOC (19f), DOCN (19j). The meta substituted compounds, such as fenfluramine
and norfenfluramine, however were found to be less active than the 3,4-disubstituted
compounds such as MDMA (17).60 Overall, the CoMSIA model for phenylisopropylamines
was internally and externally validated for 5-HT2A receptor affinities, and found to be
conservatively predictive.
2. Conformational study
This study investigated 23 phenylisopropylamines, comprising 16 molecules of the
DOX series, fenfluramine, norfenfluramine, MDA, and MDMA. LSD was included in
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subsequent studies due to the presence of the phenylisopropylamine substructure. As
discussed previously, the (R)-enantiomer is the eutomer and was hence used for
conformational study. Due to the presence of six rotatable bonds on the DOX molecule,
the conformation which was most likely to be bioactive, was to be determined as it may
exist in several low energy conformations. The crystal structures of the compounds in this
series were studied in order to compare their relative conformations in space. The
alkylamine chain in the 2,4,5-substituted DOX series might be oriented in a different plane
compared to the 3-substituted fenfluramines or the 3,4-disubstituted methylenedioxy
compounds, due to steric hindrance of the amine with the 2-methoxy substituent.
Therefore, the torsion angles of these compounds were measured before and after
minimization of the crystal structure. A major caveat of performing a conformational study
is that the molecules may not be at their global minimum (lowest energy of all the
conformers), but might exist at a local minimum energy conformation within the receptor
to fit the shape of the binding pocket. Additionally, crystal packing forces might influence
the final conformation of the molecule by restricting freely rotatable bonds. 14 Therefore,
the final conformation was based on the one in which there was minimal steric interaction
between the methoxy and the amine substituent, i.e., the alkyl chain was oriented towards
the 6-position on the phenyl ring.
The crystal structures of 2,4,5-TMA,36 MDMA,15 norfenfluramine15 and LSD36 are
known, although only the structure of MDMA was available in the Cambridge
Crystallographic Database (CCD). Furthermore, the crystal structure of DOET, the 4-ethyl
substituted DOX molecule, was also published by Horn, et al.13 and was used as an
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additional point of comparison for the DOX compounds. The torsion angles () of the
molecules about the alkylamine chain are as follows:

Table 6. Comparative study of torsion angles seen in various phenylisopropylamines.
2
1

DOEt (20)

8

2

2
1

2
1

MDMA (17)

TMA (19a)

1

Norfenfluramine (12)

Rotatable bond

DOEt
(20)

TMA
(19a)

MDMA
(17)

Norfenfluramine (12)

9

C6-C1-C7-C8 (1)

105.0

-114

108.24

110.50

2

C1-C7-C8-C9 (2) 178.0

170

-66.47

50.57

C1-C7-C8-N (3)

-61.6

50

172.5

173.99

C2-C1-C7-C8 (4)

-75.5

68

-70.14

-69.18

1
6

5

4

3

The torsion angles were obtained from the crystal structures of the
abovementioned molecules.13-15,36 The overall conformation of DOEt is similar to that of
TMA (19b), wherein the torsion angles at the -methyl groups (2) are 178 and 170
respectively. In contrast, the corresponding torsion angle in MDMA is -66.47, suggesting
the substitution pattern influences the final conformation of the molecule. The energies of
all the molecules were calculated prior to, and after minimization. The torsion angles
varied after minimization, indicating a local minimum for the particular conformation.
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Table 7. Torsion angles (2) and energies of small molecule crystal structures before
and after minimization.

Compound

Torsion
angle before
minimization

Energy
before
minimization
(kcal/mol)

Torsion angle
after
minimization

Energy after
minimization
(kcal/mol)

DOEt (20)

178

11.18

170

6.25

TMA (19a)

170

12.20

172

5.09

50.57

21.79

60.11

4.13

-66.47

75.16

-51.11

13.87

Norfenfluramine (12)

MDMA (17)

The difference seen between the torsion angles of the DOX compounds (DOEt
and TMA), norfenfluramine and MDMA suggests that there may be fewer similarities in
their binding poses as well, owing to their substitution pattern. DOI was studied in detail
to determine the various local minima that might exist. The two methoxy groups may
orient towards the same plane (the terms cis and trans will be loosely used to describe
the relative orientation of the methoxy groups) with respect to the plane of the ring.
As per the crystal structure, the methoxy groups of DOEt are oriented along the
plane of the phenyl ring, however, other low energy conformations might also exist. Since
DOI is a part of the data set, it was sketched out in various conformations and the energies
were recorded (Figure 22).
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In plane

Cis above plane

Before minimization: 9.97 kcal/mol

Before minimization: 7.10 kcal/mol

After minimization: 6.08 kcal/mol

After minimization: 4.72 kcal/mol

Rotamer with both methoxy groups
oriented towards alkylamine chain

Rotamer with both methoxy groups
oriented away from alkylamine chain

(2-methoxy flips forward by default)

(5-methoxy flips forward by default)

Before minimization: 8.74 kcal/mol

Before minimization: 8.74 kcal/mol

After minimization: 5.59 kcal/mol

After minimization: 5.59 kcal/mol

Trans methoxy groups with 2methoxy group above plane

Trans methoxy groups with 5-OMe
above the plane

Before minimization: 7.24 kcal/mol

(conformation unstable due to steric
hindrance)

After minimization: 4.87 kcal/mol

Before minimization: 7.26 kcal/mol
Afterofminimization:
5.24 kcal/mol
Figure 22. Conformational study of the methoxy groups
DOI.
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All conformations did not minimize to the same energy due to the presence of
various local minima for the molecule. The number of rotatable bonds is an overriding
factor for the number of energy minima obtained. This is not expected in conformationally
constrained molecules as they are confined to a rigid conformation and the molecule
exists in fewer energy minima, as seen in LSD. Since DOX molecules have 6 rotatable
bonds (1-4) as shown in Table 6, and one rotatable bond at each of the two methoxy
groups. The conformational study details the various low energy conformations seen in
2,4,5-substituted DOX molecules. Due to the presence of multiple rotatable bonds, the
exact bioactive conformation remains unknown. However, the conformation with the two
methoxy groups trans to each other with the 2-OMe group below the plane, was chosen
due to minimal likelihood of van der Waals’ repulsions. The energy is highly influenced
by the orientation of the methoxy group as it is in close quarters with the alkylamine
system. This is supported by the higher affinity (Ki = 0.48 nM) seen in compound 26 (R =
Br), which is conformationally constrained,73 whereas DOB (19b) has an affinity of 26.9
nM, attributed partially to its freely rotatable bonds.9
A comparative study was conducted using CoMFA and CoMSIA with the affinity
values at rat 5-HT2B receptors which were reported in the same study, to determine if the
rat 5-HT2B receptor was more sensitive to the changes at the 4-position substituent.9 Due
to the unavailability of affinity values of other molecules such as fenfluramine (11), MDMA
(17) and their metabolites (12, 18) at rat 5-HT2B receptors, the QSAR studies were limited
to the DOX series. The best CoMFA model yielded a q2 value of 0.163, suggesting that
the rat 5-HT2B receptor does not deviate far from the human 5-HT2B receptor in terms of
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sensitivity to the 4-position substitution. The CoMSIA study yielded a high q2 of 0.49 by
the exclusion of steric and electrostatic fields. This suggests a weak, if not a poor model.

Goal 2: To study the interactions of the phenylisopropylamines with the 5-HT2B
receptor.
The X-ray crystal structure of the 5-HT2B receptor was determined by Wacker et
al.12 in 2017 with the partial agonist LSD bound to the orthosteric binding site. An earlier
published crystal structure of the 5-HT2B receptor co-crystallized with ergotamine,11
revealed a difference in interactions between that of ergotamine (8) and LSD (21). While
ergotamine protrudes from the binding pocket due to its large amide moiety connected to
the ergoline system, LSD is seated more deeply in the binding pocket due to its smaller
diethylamide moiety. This additionally explains the longer residence time of LSD in the
binding pocket. Westkaemper and Glennon 85 earlier postulated a similarity of the binding
of DOX compounds with that of LSD, and that they might bind similar to LSD in the binding
pocket of the 5-HT2A receptor. On this basis, the phenylisopropylamines were docked in
the receptor and studied. The highly conserved residue Asp1353.32 is vital for forming a
salt bridge with the molecule for binding.12 Docking studies were conducted with MDMA
(17), MDA (18), fenfluramine, norfenfluramine and 16 phenylisopropylamines.
An important factor affecting the binding poses of the compounds that is taken into
consideration is that while MDMA (17) and MDA (18) are substituted at 3- and 4-positions,
fenfluramine (11) and norfenfluramine (12) are substituted only at 3-position and DOX
compounds are substituted at 2-, 4-, and 5-positions. Therefore, the three classes of

63

compounds might adopt different binding poses, and the putative antagonists in the DOX
series may adopt a distinct pose from that of agonists.
1. DOX molecules
The docking poses of the DOX series were varied and did not entirely dock in an
overlapping manner owing to the mixed functional activities that were extrapolated from
their 5-HT2A receptor activities. Low affinity of certain molecules might also explain the
differences in binding poses, thereby forming fewer interactions. In conjunction with the
affinity values and the nature of the substituent, the size of the molecules in comparison
to the ergolines were significantly smaller. Therefore, the docking radius was reduced
from 10 Å to 8 Å, resulting in tighter clustering of the molecules around the conserved
Asp1353.32 residue.
Agonists of the DOX series are hallucinogens.8 Therefore, they are assumed to
bind in a similar manner to other hallucinogens such as LSD, wherein the phenyl ring and
5-methoxy group of DOI mimic the indole nucleus of LSD by forming an open ring analog
and the 5-methoxy oxygen atom acting as the hydrogen-bond acceptor instead of
nitrogen found in LSD. However, the crystal structure of the receptor reveals the indole
nitrogen, H acts as a hydrogen bond donor to the backbone carbonyl of Gly2215.42
residue.12 Therefore, although the oxygen of the 5-methoxy group overlaps the nitrogen
of the indole nucleus, it is unable to form the same interactions as LSD, but the similarities
include the distance from the phenyl ring centroid to the amine (5.21 Å for LSD and 5.16
Å for DOI) as depicted in Figure 23, such that the aromatic ring of the ligand is able to
form interactions with the hydrophobic residues lining the binding pocket and the amine
forms an ionic salt-bridge with the highly conserved Asp1353.32 .
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A

B
5.16 Å

5.21 Å

2.72 Å

2.79 Å

Figure 23. (A) Distances from the aromatic centroid to the basic amine and indolic nitrogen
in LSD (B) Distances from the aromatic centroid to the basic amine and oxygen of the 5methoxy group of DOI.

The DOX series displayed different binding poses based on the affinity and
putative functional activities. For example, the analogs with smaller substituents than
the propyl and hexyl chains – TMA, DOF, DOB, DOC, DOI, DON, DOAC and DOCN
bind in the same manner such that they form close contact interactions with the
hydrophobic residues.
Due to the large volume and the abundance of hydrophobic residues lining the
orthosteric binding pocket, a majority of the protein-ligand interactions are hydrophobic in
nature, as can be seen from the varying affinities of the molecules with their relative
hydrophobicity. Hydropathic INTeractions (HINT) scores were measured and recorded
for all of the molecules with the receptor to validate the model and determine the
probability of the predicted binding pose. A HINT score is the sum of hydrophobic and
electrostatic interactions between any two molecules.94
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Table 8. HINT scores of DOX molecules (n = 10) with 5-HT2B receptor.

Compound

HINT score

Hydrophobic

Polar

DMA (19d)

1380.77

864.38

1085.61

DOF (19e)

2044.12

886.80

1702.91

DOC (19f)

1712.60

957.00

1534.11

DOB (19b)

1728.47

981.16

1549.37

DOI (19c)

1641.44

1016.72

1565.81

DON (19i)

1465.53

1024.15

1921.49

DOCN (19j)

1289.99

912.55

1610.46

DOAC (19h)

1370.77

1173.09

1515.22

TMA (19a)

1491.25

1090.09

1462.88

MEM (19g)

1250.06

1118.71

1067.86

In the 5-HT2A receptor, Ser2395.43 forms a hydrogen bond with the 5-methoxy
substituent of the DOX molecule, whereas the corresponding residue in the 5-HT2B
receptor (i.e., Ser2225.43 projects towards TM6, and thus, is unable to form the stabilizing
hydrogen bond as demonstrated in previous studies.96 In addition, Ser2425.46, a polar
residue, is present in the binding pocket of the 5-HT2A receptor which facilitates a
hydrogen bond with the 5-methoxy group. The 5-HT2B receptor possesses an alanine
residue (Ala2255.46) in the same position, which might explain the lower affinity of DOX
molecules at 5-HT2B receptors compared to 5-HT2A receptors. The DOX (putative agonist)
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molecule forms interactions with Asp1353.32 and Ser1393.36 (Figure 24) as was seen in
the Runyon model17, and the 2-methoxy group, with Leu209EL2, and Leu1323.29, and the
5-methoxy group with Val1363.33 and Gly2215.42. The alpha-methyl group with the
Trp3376.48, and the hydrophobic substituent at the 4-position forms a hydrophobic
interaction with the backbone of Met2185.39, Phe2175.38, and a weak electrostatic
interaction with Ser2225.43. Thus, the hydrophobic substituent is oriented towards TM5,
forming primarily hydrophobic interactions, yet not capable of forming the halogen bond,
but a weak electrostatic interaction at 3.3 Å with Ser2225.43. The isopropylamine chain is
oriented towards TM3 and TM6, forming a stable bidentate interaction with TM3. The
abovementioned residues form a subset of the residues that interact with LSD in the
receptor crystal structure.28 The unsubstituted DMA (19d) and MEM (19g) adopt different
binding poses. The poses for DMA (19d), D367 (19p) and M-154 (19o) are
unprecedented and are distinct from that of the DOX series. Although the salt bridge is
seen in all three models, the remainder of the molecule is free to form hydrophobic
interactions with other residues in the binding pocket.
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Phe2175.38

Met2185.39

Leu209EL2

Asp1353.32

Phe3406.51

Ser1393.36
Phe3416.52
Tyr3707.43

Trp3376.48

Figure 24. Structure of ligand DOB (19b) docked in the 5-HT2B receptor (PDB ID:
5TVN) represented in cyan and purple sticks, respectively. The dashed line indicates
the interactions of the protonated amine with the amino acids Asp1353.32 and
Ser1393.36 in transmembrane helix 3.

68

DOCN (19j) (Figure 25) form hydrogen bonds with the backbone of Ser222 5.43, and DON
(19i) forms a hydrogen bond with Asn3446.55. Despite these stabilizing interactions, they
may be unfavorable for the overall affinity of the molecule. DOCN (19j) has an affinity of
774 nM at the 5-HT2B receptor, while DON (19i) has an affinity of 166 nM. A Craig plot of
the nature of substituents supports these findings, since the nitrile group of DOCN has a
negative π value (+σ, -π), while the nitro group has a positive π value (+σ, +π).

Met2185.39

Leu209EL2
Phe2175.38

Val3667.39
Asp135

3.32

Ser2225.43

Ser1393.36

Tyr3707.43

Ala2255.46
Phe3406.51

Trp3376.48

Figure 25. Common docking pose of TMA (19a) (purple blue), DOB (19b) (blue), DOI
(19c) (yellow), DOF (19e) (dark green), DOC (19f) (bluegreen), DOCN (19j) (orange),
DON (19i) (lime green) and DOAC (19h)(purple).
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DOX molecules with larger 4-position substituents adopt a different binding pose in the
receptor, such that the binding pocket might accommodate the large 4-position
substituent, i.e., DOPR (19k) (n-propyl), DOHx (19l) (n-hexyl) and DOBZ (19h) (benzyl)
(Figure 30). The distance from the Asp1353.32 residue to the lower surface of the binding
pocket is not large enough to accommodate 4-position substituents larger than a certain
size. Therefore, the ring is oriented upside down such that the carbon chain accesses
secondary binding pocket residues seen in the crystal structure of ergotamine (PDB ID:
4IB4).11 Although the functional activity of these molecules is unknown at 5-HT2B
receptors, they are known to act as antagonists at 5-HT2A receptors.90 Therefore, agonists
and antagonists might adopt different binding poses in the 5-HT2B receptor for DOX
molecules. However, an exception was seen with DOPR, wherein it is an agonist at 5HT2A receptor, but adopts a putative antagonist binding mode in the 5-HT2B receptor.
Consequently, multiple binding modes were identified for phenylisopropylamines at the
5-HT2B receptor. Although these are distinct with respect to each other, they all engage
the same residues that are seen with ergolines, yet form fewer interactions.
2. Norfenfluramine isomers
The phenylisopropylamine moiety of fenfluramine is mono-substitued, whereas
most DOX molecules are tri-substituted, thereby increasing the possibilities of interactions
with the receptor binding pocket. The difference in substitution pattern between DOX
molecules and norfenfuramine or MDA influences the interaction of the molecule and their
affinity for the receptor. The protonated amine forming a salt bridge with Asp135 3.32 is the
common feature of all the molecules. A model previously proposed by Setola et al.97
suggests the involvement of Val1062.53 in TM2 in determining the stereoselective nature
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of the receptor to the R- isomer, due to the its interaction with the α-methyl carbon as
supported by mutagenesis data. Such involvement of TM2 in ligand binding was not seen
in our model. A newer model of norfenfluramine was published in the same study as the
crystal structure of the 5-HT2B receptor with ergotamine, wherein the trifluoromethyl group
forms a hydrophobic interaction with Phe217 5.38, was validated by mutagenesis to be
essential for the efficacy of the molecule.11 An F217A mutation reduced efficacy by ~10
fold.11 Our findings are consistent with this model and show the same interactions. A HINT
analysis of this model also shows it to be highly favorable. Mode 1 is similar to the newer
model and shows interactions with TM5 residues (Figure 26, 27). Mode 2 shows
interactions with TM2 (Figure 26), which is likely unfavorable, considering the residues of
TM5 are highly involved in most ligand-receptor interactions as seen from the crystal
structures.11,36,96 5-HT2B receptor functional activity of these agents remains to be
determined and will be the focus of a future study.

Table 9. HINT scores of norfenfluramine (12) isomers for both binding modes at the
5-HT2B receptor.

Compound (mode)

HINT score

Hydrophobic

Polar

RNF (mode1)

1920.43

565.36

1236.90

SNF (mode1)

2531.42

544.97

2141.04

RNF (mode2)

1434.00

557.89

1101.29
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Mode 1

Thr1142.64

Mode 2
TM5

Ser2225.43

TM5

TM2

Asp1353.32

Figure 26. Binding poses of (R)-norfenfluramine (12b) - mode 1 and mode 2. Mode 1
(pink capped sticks) shows the molecule oriented towards TM5 and mode 2 (lime
green capped sticks) towards TM2. Mode 1 is more likely to be the accurate binding
mode.
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Met2185.39
Leu209EL2

Tyr3707.43

2.6 Å
Asp1353.32

Mode 1

3.0 Å

Phe2175.38
5.43

Ser222

Gln3697.42
Thr140

3.37

Trp3376.48

Ala2255.46

Ile2253.43

Figure 27. RNF (12b) docked in the 5-HT2B receptor represented in hot pink and
deep teal sticks, respectively. A salt bridge is formed with Asp1353.32 and close
contact interactions are formed with Phe2175.38 and Met2185.39 represented in
spheres.
3. Binding modes of MDA and MDMA
The crystal structure of (S)-MDMA (17a) was used as a template to sketch and
dock the (R)-MDMA (17b) and (R)-MDA (18b) molecules in the receptor. (R)-MDA forms
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bidentate interactions with Asp1353.32 (Figure 28), while (R)-MDMA does not.

Two

binding poses were generated for the MDA molecule, mode 1 mimicking the pose of DOX
molecules, and mode 2 similar to the second pose of norfenfluramine (facing Thr114 2.64
of TM2) (Figure 29). A HINT analysis of the two poses helped establish mode 1 as the
more favorable (Table 10). Since MDMA (17) is a ring-constrained analog of 3,4dimethoxyphenylisopropylamine, and may even be compared to 2,4,5-TMA (19a). It
possesses a higher affinity than TMA (19a), indicating that the constrained methoxy
groups may be more favorable for the binding of the molecule. The lower affinity of the
molecule (100 nM) in comparison to norfenfluramine (12b) (~15 nM) and DOB (19b)(26.9
nM), however cannot be attributed to the same property. Ours is the first model of both
isomers of the valvulopathogen MDA ((S)-MDA (18a) and (R)-MDA (18b)) docked in the
5-HT2B receptor (Figure 28). It is representative of a probable binding pose of the
molecule within the receptor, and provides useful insight into the binding of a different
chemical class of valvulopathogens. The binding pose of MDMA (17) is similar to that of
MDA (18), however the N-methyl group forms unfavorable interactions with, as seen in
the final HINT score (Table 10).
The oxygen atom at the 4-position of the phenyl ring is within 3.0 - 3.5 Å of the
backbone nitrogen and -OH group of Ser2225.43, highly capable of forming a hydrogen
bond. Majority of the interactions of MDA (18) and MDMA (17) are seen in TM3
(Asp1353.32), TM5 (Phe2175.38, Met2185.39, Ala2255.46), TM6 (Asn3446.55) and TM7
(V3667.49) (Figure 28). A weak hydrophobic interaction is seen with Leu209 EL2 in the
second extracellular loop. This residue is known to be involved in recruiting β-arrestin as
highlighted by Wacker et al.12 The (S)-isomer of MDMA (17a) was found to have a similar
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binding mode as that of the (R)-isomer (Figure 28). Final HINT scores are provided in
Table 10.
Table 10. HINT scores of MDA (18) and MDMA (17) based on their binding modes.

Compound

HINT score

Hydrophobic

Polar

(R)-MDA (mode 1)

2141.39

547.93

1659.54

(R)-MDMA (mode 1)

1620.15

703.77

1488.08

(R)-MDA (mode 2)

1227.65

533.16

1066.14

(R)-MDMA (mode2)

1435.43

675.21

1080.93

(S)-MDA

1731.04

565.85

992.45

(S)-MDMA

790.60

588.46

899.44

A

Met2185.39

B

Met2185.39
Phe2175.38

Phe2175.38

Asp1353.32

Asp1353.32

Ser2225.43
Ser1393.36

Ser2225.43

Ser1393.36

Figure 28. (A) (R)-MDA (18b) in yellow and (B) (R)-MDMA (17b) in orange docked in
the 5-HT2B receptor. (R)-MDA (18b) forms bidentate interactions with Asp1353.32. The
methylenedioxy rings of (R)-MDA (18b) and (R)-MDMA (17) are within hydrogenbonding distance of Ser2225.43. MDMA (17) forms a hydrogen bond with Asp1353.32.
(Mode 1 is shown in both figures.)
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Mode 2
Asp1353.32

Mode 1

Ser1393.36

Figure 29. Binding poses of (R-MDA (18) (also seen with MDMA (17)) at the 5-HT2B
receptor. Mode 1 is represented in yellow sticks and mode 2 is shown in green sticks.
Asp1353.32 and Ser1393.36 are shown in deep teal sticks, dashed lines indicate
potential hydrogen bonds.

A

B

Phe2175.38

Met2185.39

Ser2225.43

Phe2175.38

Met2185.39
Asp135

3.32

Asp1353.32

Ser2225.43

Figure 30. (A) Binding pose of (S)-MDA (18a) at the 5-HT2B receptor shown in pale
yellow sticks. (B) Comparison of (R)-MDA (18b) and (S)-MDA (18a) binding poses
shown in bright and pale yellow sticks respectively. (Mode 1)
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A

B

Met2185.39

Met2185.39

Phe2175.38

Phe2175.38

Ser2225.43

Ser2225.43
Asp1353.32

Asp1353.32

Figure 31. (A) Binding pose of (S)-MDMA (17a) at the 5-HT2B receptor shown in pale
yellow sticks. (B) Comparison of (R)-MDMA (17b) and (R)-MDA (18b) binding poses
shown in bright and pale yellow sticks respectively.
4. Comparison of recently published crystal structures
The crystal structure of the 5-HT2B receptor was recently published with four
ligands lisuride (3), methylergonovine, methysergide (10) and LY266097 (PDB IDs:
6RDX, 6DRY, 6DRZ, 6DS0 respectively).95 This was compared against that of the cocrystal structure with LSD (PDB ID: 5TVN)12 (Table 11). The RMS deviation was
Table 11. Comparison of newly published crystal structures of 5-HT2B receptor with the
previously published crystal structure 5TVN.12

PDB ID

Ligand

Functional activity

RMSD (5TVN template)

6DRX

Lisuride (3)

Antagonist

1.05 Å

6DRY

Methylergonovine

Agonist

0.426 Å

6DRZ

Methysergide (10)

Antagonist

1.362 Å

6DS0

LY266097

Antagonist

0.725 Å
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measured in comparison to the Cα carbon of the backbone the template 5TVN. Since the
RMS value was found to be within the recommended limit of significance (<4 Å), 5TVN,
the crystal structure of 5-HT2B receptor with LSD was pursued.
5. Overview of all docking poses
DOB (19b) (taken as template for binding of DOX series molecules) and RNF
appear to bind in a somewhat similar manner (Figure 32A). This may provide clues into
the potential of hallucinogenic phenylisopropylamines to cause cardiac valvulopathy.
Figure 32B compares the binding poses of the hallucinogens DOB (19b) and LSD (21)
with a binding pose of of valvulopathogen norfenfluramine (12), in Figure 32C the binding
mode of DOB is shown with respect to valvulopathogens RNF and MDA (18). Two
binding modes are seen for the phenylisopropylamines at the 5-HT2B receptor, for
probable agonists, antagonists. Secondary and tertiary amines may bind differently in
comparison, and the 4-position unsubstituted DMA (19d) may bind differently in
comparison to the other DOX molecules as there is no substituent to be anchored by the
receptor.
A

B

C

Figure 32. (A) Docking poses of RNF (12b) (hot pink) vs DOB (19b) (blue) at 5-HT2B
receptors (B) Comparison of binding poses of RNF (12b) and DOB (19b) relative to LSD
(21)(salmon). (C) Comaprison of MDA (18) (yellow), RNF (12b) and DOB (19b).
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6. Binding mode of bulky 4-position DOX molecules

The bulky 4-position substituent cannot be accommodated between TM3 and TM5,
therefore the molecule is oriented towards TM7 wherein the volume of the cavity can
accommodate larger substituents. For example, the volume of the bromo-substituent is
43.53 Å and that of the n-Pr substituent is 137.93 Å (as calculated in Sybyl X2.1.1). The
largest substituent tolerated at the 4-position to adopt the common binding pose of DOX
molecules is 84 Å, as seen in DOAC (19h) (Sybyl X2.1.1). The Asp1353.32 – amine salt
bridge is conserved in all the receptor-ligand interactions, however while smaller
substituents are able to bind in the same manner, larger substituents are forced to orient
towards the TM7 (Figure 33).

TM7
TM5

Asp1353.32
TM3

Figure 33. Comparison of DOB (19b)and DOPR (19k) depicted as blue and yellow
capped sticks respectively, in the orthosteric binding pocket. DOPR (19k) is oriented
in the opposite direction than DOB (19b). The propyl chain is oriented towards TM7 so
as to accommodate the bulky group.
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DOPR (19k), DOBZ (19h) and DOHx (19l) are able to bind in a nearly similar
manner, yet the hexyl chain in DOHx (19l) and the benzyl group in DOBZ (19h) being
longer than the propyl chain forces the molecule to orient itself further down in the binding
pocket where there is space.
Table 12. HINT scores of DOX molecules with bulky 4-position substituents.

Compound

HINT score

Hydrophobic

Polar

DOPR

1156.22

999.22

1127.81

DOHx

1011.00

1310.01

1137.94

DOBZ

800.31

1066.11

764.08

DOTB

1389.66

1159.99

1106.95

This pose is the only one generated wherein the aspartate interaction is conserved, in
DOHx (19l) (Figure 34) and DOBZ (19h) (Figure 35) however clashes were seen in this
binding pose of the 2-methoxy group with Asp1353.32.
A

B

Asp1353.32

Asp1353.32

Figure 34. (A) DOHx (19l) (blue) and DOB (19b) (warm pink) in the 5-HT2B receptor.
(B) DOHx (19l), DOPR (19k)(yellow) and DOB (19b) (right) in the binding pocket. The
propyl and hexyl groups fit into the cavity facing the N-terminus, away from binding
pocket.
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The same binding mode is not seen with DOTB however, due to its higher volume than
length. As seen in Figure 36, it is oriented lower in the binding pocket, with the t-butyl
group facing TM7. It adopts an unique binding mode, possibly due to being a partial
agonist as seen in 5-HT2A receptors.91
B

A

Asp1353.32

Met2185.39
Phe2175.38
Ser2225.43

Figure 35. (A) DOBZ (19h) (lime green capped sticks) docked in the 5-HT2B receptor.
(B) DOHx (19l) and DOBZ (19h) (blue and lime green capped sticks respectively) in
the binding pocket. The hexyl and benzyl groups assume a similar conformation in the
secondary binding pocket region.
B

A

Leu209EL

EL

Leu209
Met2185.39

2

Met2185.39

2

Met2185.39

7.39

TM7
Val366

TM7

Phe2175.38
Asp1353.32
Phe217

5.38

Phe2175.38
Tyr3707.43

Ser2225.43

Asp1353.32

Asp1353.32
Trp3677.40
Val3667.39
Asp1353.322

2

Figure 36. (A) DOTB (19m) (white sticks) in the 5-HT2B receptor. (B) DOTB (19m)
(white sticks) and DOHx (19l) (blue sticks) in comparison. DOTB is oriented away
from the hexyl group and towards TM7.
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7. Binding of secondary and tertiary amines
D367 (19p) is a secondary amine analog of DOB (19b) with a N-propyl group and
a significantly lower (20-fold) affinity than DOB (19b). The docking simulation suggests
the molecule is situated higher than DOB (19b) in the binding pocket and forms
interactions with the Asp1353.32 and Tyr3707.43 (Figure 37). The bromine atom of D367
(19p) faces the TM5 as does DOB (19b), it does not bind in the same way as the tertiary
amine (M154 (19o)). D367 (19p) forms a single cluster upon docking and M154 (19o)
forms several clusters. The best model was chosen based on the least number of clashes
observed in the HINT scores.

7.38

7.38

A

Glu363

Glu363

B
5.39

Met218
Leu209EL2
7.40

Trp367

5.38

Phe217

Asp1353.32
5.38

Leu209EL2

7.43

Phe217

Asp1353.32

Tyr370
7.39

Val366

3.36

7.40

Ser139

Trp367

7.43

Tyr370

Figure 37. (A) D367 (19p) (secondary amine) and (B) M154 (19o) (tertiary amine)
shown in lime green and grey sticks, respectively. DOB is shown in cyan sticks in figure
A for reference.
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8. Quantitative structure-activity relationships
The DOX molecules seemed to show a pattern of increasing 5-HT2B receptor
affinity with lipophilicity of the substituent at the 4-position (Table 13), which was also
supported by our CoMSIA studies (Figure 18). In order to examine this, we conducted a
correlation of the pKi vs -value for the varied substituents (n = 14).9,98 A positive
correlation (r = 0.753) was obtained for the 𝜋-values, with two clusters of points (Figure
38); however there was a poor distribution of affinity values of the compounds. The p
value was below 0.05 and was therefore considered to be statistically significant. The
correlation coefficient was improved (r =0.78 ) if DOHx was deleted from the set, therefore
an outlier test was conducted to determine if DOHx was an outlier in the data set. The
analysis was performed using the Statistical Package for the Social Sciences (IBM SPSS,
New York, NY).

DOHx
DOPR

DON
DOAC

Figure 38. Plot of pKi values of the DOX molecules versus the 𝜋 values of the 4position substituent (r = 0.753, p = 0.0018, n = 14).
The Z-score provides a standard deviation of 1 and a mean of 0, therefore a Z-score of
>3 would indicate an outlier that is two standard deviations away from the original 1. The
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range of Z-scores obtained (i.e., multiple agents were examined, including DOHx) was 1.38 to 1.45, suggesting there were no outliers in this model.
Table 13. QSAR parameter values for DOX series (n = 14)

Name

pKi (5-HT2B)

π-value98

Volumea

DMA

5.98

0

690.29

DOCN

6.11

-0.57

736.02

MEM

6.12

0.38

798.02

DOAC

6.5

-0.55

774.66

TMA

6.51

-0.02

752.38

DOF

6.64

0.14

700.52

DON

6.78

-0.28

748.64

DOPR

7.26

1.55

828.22

DOBZ

7.46

2.01

950.22

DOC

7.5

0.71

721.46

DOHx

7.52

3.1

987.63

DOB

7.57

0.86

733.82

DOTB

7.61

1.98

850.36

DOI

7.7

1.12

748.20

aCalculated

for the entire molecule using SYBYL X2.1.1.
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The volume of the substituents (calculated in Sybyl X2.1.1) was also investigated
for their influence on the affinity of the molecules (Table 13). A poor correlation was
affinity. Figure 39 shows a plot of the volume plotted against the affinity of the molecule.
However, when the -value of the 4-position substituent was plotted against the volume

pKi value (h5-HT2B)

Figure 39. Plot of pKi values of the DOX molecules versus the volume of the 4position substituent (r = 0.455, p = 0.101, n = 14)
of the substituent, a strong positive correlation was seen (r = 0.819) (Figure 40).
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DOHx

DOAC

Figure 40. Positive correlation between the -value and the volume of 4-position
substituents (r = 0.819, p = 0.0003, n = 14).

The anomaly of a high correlation between hydrophobicity () and volume, but a low
correlation between pKi and volume was further investigated with a multiple regression
analysis (Eq. 1).
y = 0.66 () - 0.003 (volume) + 10.30

(Eq.1)

(n = 14; F = 10.11; r = 0.80; Standard error = 0.40)
The r value obtained was 0.80, and the ANOVA test resulted in the coefficients for 𝜋 and
volume to be 0.66 and -0.003, respectively. The overall p value was 0.001, indicating the
results to be statistically significant. The overarching conclusion of this study is that the
high affinity DOX molecules is due to a highly hydrophobic 4-position substituent, as also
evidenced by docking studies wherein the orthosteric binding pocket is abundantly lined
with hydrophobic residues.
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V. Conclusions
The overall purpose of this study was to establish the potential of hallucinogens in causing
cardiac valvulopathy mediated by agonism of 5-HT2B receptors, by examining their
structure-activity relationships and determining their interactions with the receptor. In the
culmination of these studies, we found DOX molecules to adopt different binding poses
owing to the varying size and nature of the 4-position substituents and the presence of
primary, secondary, tertiary and quaternary amines.
The

1

first

structure-activity

relationships

of

phenylisopropylamines as hallucinogens at 5-HT2B receptors

2

obtained from CoMSIA and statistical analyses suggest:
4
1. Primary amines are optimal for 5-HT2B receptor binding.
2. The 2-OMe group appears unessential for 5-HT2B affinity.
3
3. A substituent (electron-rich) seems to contribute.
4. Lipophilicity of the 4-position substituent as suggested by its
π value, seems to contribute to 5-HT2B receptor affinity. This
might explain the (reduced) affinity of MDMA.
Having said this, it remains to be determined which of these agents in Table 2 act as
agonists or antagonists. Agonists and antagonists might bind in a different manner. The
DOX molecules investigated in the abovementioned studies were docked in the 5-HT2B
87

receptor to study their interactions with the receptor. With the co-crystal structure of the
receptor (PDB ID: 5TVN), we were able to compare two classes of hallucinogens
ergolines and phenylisopropylamines (LSD and DOX). DOI has the highest binding
affinity of all DOX molecules for the 5-HT2B receptor. It occupies the same area as the
LSD molecule, and the 5-methoxy substituent overlaps the indolic nitrogen of LSD.
Similarities are seen with LSD and DOI such as the Asp135 3.32 – amine salt bridge, the
aromatic interactions seen with residues in transmembrane helices 3, 5, 6, and 7.
Common hydrophobic residues seen for DOI and LSD in the orthosteric binding pocket
are Phe3406.51, Phe3416.52, Val1363.33, and Ala2255.46. Interaction with Leu209EL2 in the
extracellular loop-2 causes engagement of ß-arrestin as evidenced in the co-crystal
structure with LSD (PDB ID: 5TVN). The iodo-substituent of DOI forms hydrophobic
interactions with Leu209, suggesting that DOI may also be involved in ß-arrestin
recruitment, yet there is not sufficient evidence to pinpoint if it has potential to cause
cardiac valvulopathy. The DOX molecules with bulky 4-position substituent adopt an
‘inverted’ binding pose. The substituents engage residues in TM3 and TM7, as seen in
ergotamine, which possesses a large amide substituent. These molecules are known to
act as antagonists at 5-HT2A receptors, providing us with evidence to predict their
functional activities as well. An exception is seen with DOPR, as it is known to be a
hallucinogen, (5-HT2A agonist) but has the binding mode of a putative antagonist at the
5-HT2B receptor. Hence, there is a structure-activity relationship observed, wherein the
affinity of DOX molecules increases with hydrophobicity. This is not, however, seen with
the volume of the substituents.
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Overall, putative agonists of the phenylisopropylamine class all appear to adopt a similar
binding pose such that the phenyl rings are more or less overlapping, and the
substituents interact with the same residues. Norfenfluramine, MDA, and DOX molecules
show similar binding modes in the docking studies. The differential binding modes,
however, present as a caveat when conducting 3D-QSAR studies, since the alignment
of molecules are based on the assumption that they all adopt a similar binding mode
The bulky 4-position-substituted (greater than 84 Å) DOX molecules adopt a different
binding pose in comparison to accommodate the bulk of the molecule, as seen with
DOPR, DOHx and DOBZ. The three substituents have high affinity as they access the
secondary binding pocket residues in TM7. Therefore, the series might consist of
agonists, partial agonists and antagonists. Functional activity studies are underway to
determine the nature of the DOX molecules. The present studies suggest that the
functional activity of DOX analogs at 5-HT2A receptors might not be consistent with their
functional activity at 5-HT2B receptors. This remains to be determined.
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VI. Experimental

A. CoMFA and CoMSIA

1. Software and Hardware
Conformational analyses and CoMFA studies descried here were carried out on
Sybyl X2.1.1, a molecular modeling package available from Tripos Inc. Calculations were
performed on a UNIX workstation at Virginia Commonwealth University (Department of
Medicinal Chemistry).
2. Sketching of molecules
All structures were sketched and minimized in Sybyl X2.1.1. The structures were
minimized under Tripos force fields using Gasteiger Hϋckel charges and subject to
100,000 iterations. The dielectric constant was set at 4 to mimic the environment of the
protein. Since the (R)-enantiomer was the eutomer for phenylisopropylamines at 5-HT2A
receptors, all structures were sketched with the (R) configuration. All the amines were
protonated, as found in the protein. Phenylisopropylamines exist in several energy
minima, and were hence sketched and minimized with various templates using the crystal
structures of 5-HT2B receptor ligands keeping in mind the multiple rationale that may
dictate how the molecule may bind at the receptor. Initial studies were conducted by
obtaining the co-crystal structure of LSD with the 5-HT2B receptor, deleting the atoms
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except those in the basic scaffold of phenylisopropylamines, and sketching the remainder.
Acknowledging that the bioactive conformation of LSD co-crystal structure12 does not visit
the conformation seen in its small molecule crystal structure,36 we chose the former. The
biological data (affinity/Ki) of the molecules was obtained from the study conducted by
Nelson, et al.9 The Ki values of the compounds were expressed in molar units and
converted to their negative logarithmic value (-log Ki = pKi). The molecules were sketched,
superimposed and saved in a molecular database (.mdb file), and the corresponding pKi
values were imported into a spreadsheet in Sybyl X2.1.1.
3. Alignment of molecules
The alignment is a crucial step in determining the quality of the model. With a view
to ensure maximum overlap of the compounds present in the data set, three non-coplanar
points were chosen to get a reliable model for 3D-QSAR analyses. Various alignments
were used to obtain suitable overlap, with the lowest root mean square (RMS) deviation
value being favorable. Following are the RMS values for each alignment. (Figure 41)
Since alignment 1 brings about overlap of the vital components of the molecule, it was
pursued for future CoMFA studies. A low RMS value may not necessarily include atomto-atom overlap of the important components of the molecule.

Alignment 1

Alignment 2

RMS value range:
0.001-0.089

Alignment 3

RMS value range:
RMS value range:
0.002-0.05
0.002-0.6
Figure 41. Alignment of compounds attempted based on three non-coplanar points.
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4. Calculation of CoMFA and CoMSIA descriptors
The studies were conducted on Sybyl X2.1.1 molecular modeling software suite.
Steric and electrostatic interactions were calculated using an sp 3 hybridized carbon atom,
and a (+1) charge as steric and electrostatic probes, respectively, in a grid with 2-Å
spacing. Default values were of 30 kcal/mol was set as the maximum steric and
electrostatic energy cutoff. During calculations of field energies at the lattice points, some
values may exceed the selected cutoffs for electrostatic and steric energies. For the PLS
analysis, the minimum column filtering was set at 2.0 kcal/mol to improve the signal to
noise ratio by omitting those lattice points where energy variation was below the
threshold. The column filtering value is the minimum level of energy variation allowed for
a lattice point to be included in the PLS analysis. It can be reduced to improve the
sensitivity of the PLS analysis. The following regression analysis was performed using
the cross-validation by leave-one-out (LOO) method. The non-cross validated analysis
was performed with the optimal number of components that yielded the highest R 2CV (q2)
and the correlation coefficient r2. The standard error of prediction values were also
obtained in this study.
5. Partial least squares (PLS) analysis for CoMFA
The CoMFA study is performed by calculating and comparing the molecular steric
(Lennard Jones) and electrostatic (Coulombic) fields of both active and inactive analogs.
The energy values obtained are entered into columns in a CoMFA QSAR table. The table
consists of thousands of descriptors for each molecule. A PLS analysis correlates these
descriptors with the molecular structure and in turn, to the biological activity. The leaveone-out method and PLS analysis provide a statistically significant final CoMFA equation.
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The result of this analysis is a ‘cross validated r 2’ (also known as q2), an indicator
of the quality of the model. A q2 value of >1.0 suggests the model equation is predictive
and when its value is negative, the model is not predictive. At 0.5, a q2 value is considered
significant. Optimum number of components is chosen for a non-validated analysis.
Ideally, the number of components is 1/3 rd of the total number of compounds. PLS
analysis explains the differences in biological activity based upon the descriptors used in
the calculations and the interactions of the molecules within the grid.

6. Selection of training set and test set
The training set was chosen to represent all electronic and steric characters of the 4position substituents. The test set comprised of the remainder molecules, as described in
the results and discussion section. The training set and test set were divided into 75%
and 25% respectively.
7. Leave-one-out (LOO) method of cross validation for CoMFA
The leave-one-out method excludes one compound from the data set and a CoMFA
model is generated to predict the biological activity of the deleted compound. This method
validates the model externally by predicting the activity of a molecule absent from the
dataset. The residual sum of squares or predicted residual error sum of squares (PRESS)
describes the margin between the predicted versus actual biological activity, and the
cross validated standard error of estimate (sCV) provides the margin of error for the overall
model. This method is run several times by deleting one molecule at a time each time
generating a CoMFA model, typically based on the number of molecules present in the
93

data set. The final q2 value determines the quality of the model and its predictivity,
provided the model is not overfitted.

8. PLS analysis for CoMSIA
The steps for CoMFA and CoMSIA are the same, up to the alignment step. The PLS
analysis for CoMSIA is different from that of CoMFA since there are five types of
dependent variables calculated for the molecules of the data set: hydrogen bond donor,
hydrogen bond acceptor, hydrophobic properties, steric, and electrostatic properties.
CoMSIA differs from CoMFA in that it accounts for the similarity of the molecules in the
study and provides a statistical correlation for the trends seen in that data set.
In a CoMSIA study (Table 14), the result consists of contribution of each field (donor/
acceptor/ hydrophobic/ steric/ electrostatic) and the q 2 value with the standard error of
estimate. A dependent variable column can be excluded if it has less than 15%
contribution to the model. Provided in Table 15 is the output obtained for the CoMFA
models generated. The column filtering was reduced to ‘fine tune’ the q 2 value of the
model. However, the pursuit of obtaining a high q 2 value bears certain risk of overfitting
the model, and was hence not attempted any further.
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contribution)

dropped (low

Electrostatic

contribution)

(low

Excluded donor

(n = 16)

amines dropped

2 and 3

-

-

0.1

15

n = 20 (column

filtering default)

13

(%)

settings

n = 20

Donor

Experimental

14

15

15.1

20

18.4

(%)

Acceptor

68.7

60.8

56.4

50.5

45

(%)

Hydrophobic

16.1

11.8

14.9

11

12

(%)

Steric

-

0.07

0.01

8

15

(%)

Electrostatic

5

5

6

4

4

0.01

0.01

0.01

2

0.01

filtering

number of
components

Column

Optimum

0.49

0.49

0.49

0.33

0.36

q2

Table 14. h5-HT2B receptor affinities based CoMSIA study output.

Table 15. CoMFA study conducted on rat 5-HT2B receptor affinity values.
Experimental

Std. error of

Column

Optimal

Grid

CoMFA

settings

prediction

filtering

number of

spacing

q2

(kcal/mol)

components

Default

0.731

2

2

2Å

-0.110

Reduced grid

0.732

2

2

1Å

-0.113

0.744

1

2

2Å

-0.115

0.635

2

2

2Å

0.163

0.635

1

2

2Å

0.163

0.635

2

2

1Å

0.163

spacing
Reduced column
filtering

H-bond
parametera

H-bond parameter
(reduced column
filtering)
Reduced grid
spacing

aSteric

and electrostatic cutoff 50 kcal/mol

In order to further understand the models with low q 2 values for the human 5-HT2B
CoMFA, a comparative study was conducted with rat 5-HT2B receptor affinities (Table 15
for CoMFA and Table 16 for CoMSIA), and subsequently with the human 5-HT2A receptor
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affinities. The data for 5-HT2A receptor was found to be highly sensitive to changes in the
4-position substituents, a good range of affinity values were available. Table 17 and 18
provide the output obtained for CoMFA and CoMSIA models for 5-HT2A receptors
respectively.

9. CoMSIA on rat 5-HT2B values
The CoMSIA studies using 5-HT2B receptor binding affinity data were conducted to
investigate if the quality of the model might improve by modulating various factors
influencing the quality of the model (for example, column filtering, grid spacing, and
number of dependent variable columns used for PLS). As Table 16 suggests, these
factors play but a minor role in comparison with the biological activity data range. The q 2
value remains within a narrow range of 0.44-0.49, indicating the experimental settings,
default or otherwise were suitable for obtaining a good CoMSIA model.
According to study conducted by Nelson et al.,9 the affinity values of human 5-HT2B and
rat 5-HT2B receptors were similar with a ratio of h5-HT2B/r5-HT2B ranging between 0.3 and
1.6. Therefore, these results were not entirely unexpected, owing to the narrow affinity
range at r5-HT2B receptors as well.
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15.3

15.3

Default

Column

98

(low

spacing 21.2

reduced to 1Å

Grid

contribution)

(low

Steric dropped 21.2

contribution)

dropped

Electrostatic

reduced
21.3

%

settings

filtering

Donor

Experimental

17.4

17.4

17.2

10.2

10.2

%

Acceptor

61.5

61.5

49.4

5.29

52.9

%

Hydrophobic

-

-

12.1

12.9

12.8

%

Steric

-

-

-

8.88

2

0.1

2

0.1

2

filtering

static %

8.88

Column

Electro-

3

3

4

3

2

components

number of

Optimal

0.45

0.49

0.47

0.44

0.44

q2

Table 16. CoMSIA studies conducted on rat 5-HT2B receptor data with variations in

experimental settings.
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contribution)

dropped

Acceptor

contribution)

dropped

Electrostatic

(low
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Default (n = 21)

n = 20

n = 16

settings

Experimental

8.4

-

18.2

9

10.4

12.7

%

Acceptor

20.3

16.5

9.8

13.8

%

Donor

56.2

50.9

50.4

55.4

47

%

25.5

20.4

14.5

15.6

22.5

%

Hydrophobic Steric

-

-

8.6

8.8

4

%

-static

Electro

-

2

2

2

2

filtering

Column

4

5

5

5

5

components

number of

Optimal

0.80

0.809

0.803

0.84
(pursued for
investigation)

0.606

q2

Table 17. CoMFA studies on human 5-HT2A receptor affinities.

Experimental
Number of
Column
Optimal
. CoMSIA
on human filtering
5-HT2A affinities
.
settings
compounds
number
of
components

Grid
spacing

q2

Default

n = 16

2

4

2Å

0.398

Default

n = 17

2

3

2Å

0.402

Increasing
number of
compounds

n= 21

2

4

2Å

0.68

B. Docking and HINT analysis
1. Docking software
The molecules were docked using GOLD 5.4 (Cambridge Crystallographic Data Centre,
Cambridge, UK) into the crystal structure of the 5-HT2B receptor (PDB ID: 5TVN). GOLD
is a program which uses genetic algorithm to find the best possible binding pose of the
ligand in the receptor. The γ-carbon of conserved orthsteric binding pocket residue
Asp1353.32 was used to define the binding site and the radius was set at 10 Å around the
residue. The model was first validated by re-docking the co-crystallized ligand (LSD) into
the receptor and observing the solutions. LSD was docked thirty times, forming a single
cluster with all poses matching that of the crystal structure and a robust ChemPLP score
(80.48). The other ligands docked were molecules of the DOX series, both isomers of
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MDMA, MDA, fenfluramine and norfenfluramine. Although their ChemPLP scores were
lower than that of LSD (ranging from 40-50), it is not anamolous to obtain lower scores
for a different class of molecules that were docked into the receptor.

2. Visualising and minimization of protein-ligand complexes
The docked ligands were merged with the receptor and minimized in Sybyl X2.1.1. The
staged minimization function minimizes the protein side chains as well as the carbon
backbone. Parameters for minimization were set in the same manner as that for
sketching the molecules. The dielectric function was set at 4.0, using Gasteiger-Hückel
charges in a Tripos force-field. The molecules were than extracted from the merged file
and visually inspected for hydrogen bonding and other interactions with the receptor
residues. Images were generated using PyMOL (Schrödinger, LLC, New York, NY)

3. HINT analysis
The HINT program is invoked from Sybyl 8.0 software. A HINT analysis provides a
detailed report of the interacions of the ligand seen with the protein.94 It helps quantify
the level of interaction of the molecule with the receptor. The protein was partitioned
using the dictionary option with the default settings.
4. Statistical analyses
All statistical analyses were performed on GraphPad Prism 8.0.0 (Graphpad Software
Inc, La Jolla, CA), the Z score test was generated on the Statistical Program for the
Social Sciences (SPSS, IBM, New York, NY).
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